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ABSTRACT OF THE DISSERTATION

A Mouse Model of Börjeson-Forssman-Lehmann Syndrome reveals a potential link with
Autism Spectrum Disorder
By
Cheng Cheng
Doctor of Philosophy in Biology and Biomedical Sciences
Developmental, Regenerative and Stem Cell Biology
Washington University in St. Louis, 2018
Dr. Azad Bonni, Chair

Intellectual disability (ID) is a prevalent neurodevelopmental disorder that affects 1% to
3% of the general population. ID is characterized by developmental deficiencies in cognitive
function and adaptive behaviors. Lacking effective treatments, ID currently presents an immense
burden to affected families and the economy. Therefore, there is an urgent need to elucidate the
pathogenesis of ID. Human genetic studies have associated ID with a number of gene mutations.
ID can be divided into two major groups: a non-syndromic form, characterized by intellectual
impairment manifesting alone, and a syndromic form, characterized by both cognitive
deficiencies and other anomalies, including biochemical disorders, skeletal abnormalities, facial
dysmorphisms and neurological disorders. However, scientists have limited their studies to
relatively few syndromic forms of ID, such as Rett, Angelman and Fragile X syndrome. In
addition to these commonly studied syndromes, Börjeson-Forssman-Lehman syndrome (BFLS)
ix

was identified over five decades ago as a cause of X-linked ID and characterized as a syndromic
form of moderately to severely impaired cognitive function associated with early developmental
delay, truncal obesity, small genitalia, facial dysmorphism and seizures. Whether BFLS patients
display other neurological manifestations besides cognitive impairment and seizures remains
unexplored. In particular, whereas some genetic forms of ID are accompanied by manifestations
of autism spectrum disorders (ASD), whether BFLS also features symptoms and signs of ASD is
unknown. Forty years after the first description of BFLS, mutations in the gene encoding plant
homeofinger protein 6 (PHF6) were discovered to be causative for BFLS. These mutations are
distributed throughout the entire gene in distinct domains of PHF6, and are composed of
missense, nonsense, truncation, duplication and frameshift. Accumulating evidence suggests that
PHF6 plays a role in transcriptional regulation. PHF6 contains nuclear localization sequences
and PHD domains and can interact with transcriptional elongation complex, PAF1 to regulate
cortical neural migration. Furthermore, other studies also suggest that PHF6 may regulate
transcription through association with the nucleosome remodeling complex NuRD and upstream
binding factor UBF1. The discovery of PHF6 interactors and their functions during neural
development have raised additional interesting questions in understanding BFLS pathogenesis.
How does PHF6 regulation of gene expression at the genome-wide level impact BFLS
pathogenesis? How do specific PHF6 mutations trigger the pathogenesis of BFLS? Within this
thesis, I provide detailed characterization of a mouse containing a patient-specific mutation of
PHF6 as a novel BFLS model. Mice with the patient-specific PHF6 C99F mutation display
deficits in cognitive function, emotionality and social behaviors, and are more susceptible to
seizures, suggesting that PHF6 C99F mice feature phenotypes relevant to BFLS. In
electrophysiological studies in acute slices, the intrinsic excitability of entorhinal cortical layer II
stellate neurons is increased, providing mechanistic basis for susceptibility of BFLS mice to
seizures. Genome-wide RNA-Seq analyses of the cerebral cortex show that PHF6 promotes the
expression of neurogenesis genes and concomitantly suppresses the expression of synaptic genes,
suggesting that PHF6 promotes an immature state of neurons. Strikingly, bioinformatics analyses
x

reveal that PHF6-regulated genes are overrepresented by ASD relevant gene signatures including
modules that are misregulated in single gene causes of ASD. Consistent with these findings, we
have identified an ASD patient with an underlying PHF6 missense mutation. Collectively, our
findings in the novel BFLS mouse model broaden our understanding of the clinical features of
BFLS patients and elucidate cellular and molecular underpinnings of BFLS pathogenesis.
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Abstract
Intellectual disability encompasses a large set of neurodevelopmental disorders of
cognition that are highly prevalent. Intellectual disability is more common in males than females,
and accordingly mutations in over 100 X-linked genes that cause intellectual disability have been
identified. However, whereas a few X-linked intellectual disability proteins have been
intensively studied, the molecular mechanisms underlying the majority of X-linked intellectual
disability disorders remains poorly understood. A substantial fraction of X-linked intellectual
disability genes encode nuclear proteins, suggesting that elucidating their functions in the
regulation of transcription may provide novel insights into the pathogenesis of intellectual
disability. In this regard, recent studies have begun to elucidate the mechanisms by which
mutations of the gene encoding PHF6 contribute to the pathogenesis of the X-linked intellectual
disability disorder Börjeson-Forssman-Lehmann syndrome (BFLS). Mutations of the PHDcontaining protein PHF6 were identified over a decade ago as the cause of BFLS. However, until
recently the function of PHF6 in brain development remained unknown. Recent studies have
revealed that PHF6 plays a critical role in the migration of neurons in the mouse cerebral cortex
in vivo. Remarkably, PHF6 physically associates with the PAF1 transcriptional elongation
complex and thereby drives neuronal migration in the cerebral cortex. Other studies have
identified an interaction of PHF6 with the NuRD chromatin remodeling complex and nucleolar
transcription factor UBF. Interestingly, PHF6 mRNA has been identified as the target of the
microRNA miR-128 in the cerebral cortex, providing new insights into how PHF6 function in
neuronal migration is regulated. Importantly, deregulation of PHF6 function in neuronal
migration triggers the formation of white matter heterotopias that harbor neuronal
hyperexcitability, which may be relevant to the pathogenesis of intellectual disability and
seizures in BFLS. Collectively, these studies are beginning to provide insights into the molecular
pathogenesis of BFLS and pave the way for future studies that will significantly improve our
understanding of X-linked intellectual disability.
2

X-linked Intellectual disability is a prevalent neurodevelopmental disorder
X-linked intellectual disability (XLID) affects 1 to 3 percent of the population (Bhasin et
al., 2006; van Bokhoven and Kramer, 2010; Larson et al., 2001). Clinically, XLID is
characterized by a deficit in intellectual function with an intelligence quotient (IQ) of less than
70 before the age of 18 and impairment of adaptive behaviors leading to deficient
communication and social interactions (van Bokhoven and Kramer, 2010). Based on IQ score,
intellectual disability may be classified as IQ: profound (IQ<20), severe (IQ 20-34), moderate
(IQ 35-49) and mild (IQ 50-69) (Ropers, 2010). XLID affects more males than females (Ropers,
2010). XLID has been grouped into syndromic and nonsyndromic forms. Nonsyndromic XLID is
characterized by intellectual disability in the absence of other symptoms or signs, whereas
syndromic XLID patients display intellectual disability together with other developmental
abnormalities (Kleine-Kohlbrecher et al., 2010). Gene deletions, duplications, inversions and
point mutations on the X chromosome have been associated with XLID. Thus far, mutations in
over 100 genes on the X chromosome have been associated with intellectual disability. These
mutations affect proteins with functions in transcription, translation, signal transduction and cell
cycle regulation (Kleine-Kohlbrecher et al., 2010).
Characterization of XLID-associated proteins has opened up new fields of study in brain
development and disease. The X-linked fragile X and Rett syndromes represent two major
examples of XLID syndromes that have spawned major lines of research at the intersection of
development and cognitive disorders of the brain. Characterized by intellectual disability, autistic
features, developmental delay, hyperactivity and attention deficit behavior (Coffee et al., 2008;
Huber et al., 2002; Leigh & Hagerman, 2013), fragile X syndrome is caused by expansion of
CGG nucleotide repeats in the 5’ untranslated region of the Fmr1 gene, leading to its
transcriptional silencing (Verkerk et al., 1991; Yu et al., 1991). A large number of studies have
elucidated functions for the Fmr1-encoded protein, FMRP in protein translation and synaptic
plasticity (for review, see Leigh & Hagerman, 2013). In the mutant mice lacking FMRP, long3

term depression triggered by metabotropic glutamate receptors activation is enhanced (Bhakar et
al., 2012; Huber et al., 2002). In the cerebral cortex, FMRP knockout mice have increased
dendritic spine number with more immature long shaped spines but fewer spines with mature
mushroom shape (Irwin et al., 2000). Thus, FMRP regulates both synaptic development and
plasticity. At a molecular level, FMRP operates as an RNA-binding protein to control mRNA
stability (Zalfa et al., 2007). FMRP may enter the nucleus and assemble with targeted RNAs into
mRNP and undergo export to dendrites and regulate local protein synthesis (Eberhart et al.,
1996). In fragile X syndrome patients, loss of FMRP function causes deregulation of localized
mRNA synthesis, leading to defects in synapse function (Comery et al., 1997; Jin and Warren,
2000).
Rett syndrome patients have normal psychomotor development for the first 6 months
after birth but subsequently fail to attain psychomotor milestones and eventually lose language
and hand skills (Samaco and Neul, 2011). Mutations in methyl CpG binding protein 2 (MeCP2)
cause Rett syndrome (Amir et al., 1999). MeCP2 knockout mice behave normally before
weaning age (Guy et al., 2001), but by week eight these mice have unstable gait and reduced
spontaneous movement followed by hindlimb clasping (Guy et al., 2001). Induced pluripotent
stem cell (iPSC)-derived neurons from patients with Rett syndrome have reduced spine density,
soma size and glutamatergic synapses (Marchetto et al., 2010), mimicking neuropathological
findings on the brains of Rett syndrome patients (Kaufmann and Moser, 2000; Reiss et al., 1993;
Samaco and Neul, 2011). MeCP2 binds to methylated cytosine within CpG motifs and has been
implicated in the regulation of transcription (Nan et al., 1997). MeCP2 may silence transcription
by recruiting co-repressors including histone deacetylases (Hdacs) (Nan et al., 1998; Skene et al.,
2010). Remarkably, MeCP2 binds to methylated CA motifs within long genes (> 100 kb) to
repress transcription, and upon MeCP2 depletion long gene expression is increased (Gabel et al.,
2015). Although MeCP2 accumulates in post-mitotic neurons, MeCP2 may also play a role in
glial cells and mutations of MeCP2 in glial cells may cause non-cell autonomous defects in
neurons (Ballas et al., 2009).
4

Studies of FMRP and MeCP2 illustrate that significant advances in our understanding of
neural development and pathogenesis of intellectual disability can be achieved from systematic
studies of individual XLID proteins. Therefore, characterization of PHF6 is likely to yield novel
insights into our understanding of brain development and intellectual disability.
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Börjeson-Forssman-Lehmann syndrome (BFLS)
The Börjeson-Forssman-Lehmann syndrome (BFLS) was first described as an X-linked
intellectual disability syndrome by Mats Börjeson and colleagues in 1962 (Börjeson et al., 1962).
Since then, additional cases of BFLS patients have been identified. A summary of the clinical
features of BFLS is presented in Table 1. BFLS patients typically have normal birth weight, head
circumference and delivery (Lower et al., 2002). However, the main clinical features of BFLS
become apparent with age and show considerable variation among different patients (de Winter
et al., 2009; Lower et al., 2002). Developmental delay usually appears before the first birthday.
All BFLS patients have intellectual disability, ranging from mild to severe, as well as small
genitalia and short stature (Gécz et al., 2006; Lower et al., 2002). Approximately 75% of the
patients have obesity emerging in late childhood; BFLS patients display microcephaly or
macrocephaly at a frequency of 6% and 15% respectively; Epileptic seizures have been observed
in approximately 8% patients (Carter et al., 2009; Di Donato et al., 2014; Mangelsdorf et al.,
2009; Zweier et al., 2013). Other features of the syndrome include tapered fingers and broad
foreshortened toes. Adult BFLS patients display some coarsening of facial features with
prominence of the supraorbital ridges and deep-set eyes (Gécz et al., 2006; Lower et al., 2002).
Other abnormalities observed uncommonly in BFLS patients include mild polyneuropathy,
hearing impairment, cleft lip and hypopituitarism (Gécz et al., 2006). Female carriers of BFLS
may have learning problems and show physical manifestations including shortened toes,
thickened fleshy ear lobes, pronounced supraorbital ridges and deep-set eyes (Gécz et al., 2006;
Lower et al., 2002).
Molecular genetics studies have led to the identification of multiple mutations in the
PHF6 gene on the X chromosome in BFLS patients (Berland et al., 2011; Carter et al., 2009;
Lower et al., 2002; Turner et al., 2004). Most PHF6 mutations in BFLS are missense or lead to
truncation of PHF6 protein. Five PHF6 mutations in BFLS are recurrent including
c.2T>C/p.M1T, c134G>A/p.C45Y, c769A>G/p.R257G, c.999-1001delTGA/p.D333del and
c1024C>T/p.R342X, found in 21% of patients. The truncation mutation c.1024C>T/p.R342X is
6

found in five different BFLS families (Chao et al., 2010; Crawford et al., 2006; Lower et al.,
2002, 2004). The majority of PHF6 mutations occur in exon 2, which encodes the N-terminus of
PHF6 protein. A fundamental question that remains to be addressed is how PHF6 mutations lead
to BFLS.

7

Mechanisms of PHF6 function
The PHF6 gene is comprised of 11 exons that is transcribed into a 4.5 kb mRNA and
translated into a 41 kDa protein with 365 amino acids. Two major isoforms of PHF6 mRNA,
depending on whether intron 10 is spliced out, give the same protein product (Gécz et al., 2006).
PHF6 protein is highly conserved in vertebrates. Structurally, PHF6 protein contains two plant
homeodomain (PHD)-like zinc fingers, two nuclear localization sequences and a nucleolar
localization sequence (Liu et al., 2014a), suggesting that PHF6 may play a role in the regulation
of transcription. PHD zinc fingers are structurally conserved modules that interact with
chromatin or mediate protein-protein interactions (Sanchez and Zhou, 2011). The Cys4-His-Cys3
motifs within the PHD domain of PHF6 coordinate two Zn2+ ions and stabilize PHF6 protein
structure (Liu et al., 2014a). The evolutionary conserved PHF6 cysteine residues C45, C99 and
C305 are targeted by missense mutations in BFLS. PHD fingers also recognize specific histone
modifications (Aasland et al., 1995; Sanchez & Zhou, 2011; Wysocka et al., 2006), and regulate
the function of epigenome readers in transcription via molecular recruitment of multi-protein
complexes. However, unlike other PHD domain proteins, PHF6 contains two imperfect PHD
domains (Liu et al., 2014a). Therefore, it is unclear whether the PHD domains in PHF6 function
similarly as other PHD domains to recognize specific chromatin marks or participate in
recruitment of other proteins.
Employing an unbiased computation-assisted proteomics approach, Zhang et al.
discovered that PHF6 associates with subunits of the PAF1 transcription elongation complex
including PAF1, LEO1, CTR9, and CDC73 (Zhang et al., 2013). The interaction of PHF6 with
the PAF1 complex plays a critical role in PHF6 function in neuronal migration in the cerebral
cortex. Knockdown of PAF1 mimics the PHF6 knockdown-induced phenotype of impaired
neuronal migration in the mouse cerebral cortex (Zhang et al., 2013). Both PHF6 and the PAF1
complex induce expression of the gene encoding Neuroglycan C, which in turn mediates the
ability of PHF6 and PAF1 complex to promote neuronal migration (Zhang et al., 2013).
Knockdown of Neuroglycan C phenocopies the effect of PHF6 knockdown and PAF1
8

knockdown on neuronal migration, and expression of Neuroglycan C in PHF6-depleted
progenitors rescues the defects in neuron migration (Zhang et al., 2013).
The PAF1 complex occupies the promoter and gene body of actively transcribed genes
and associates with RNA polymerase II (PolII) to promote transcriptional elongation and
transcription-coupled histone modifications (Chen et al., 2009; Krogan et al., 2002; Marton &
Desiderio, 2008; Rondon et al., 2004; Squazzo et al., 2002). The C-terminal domain (CTD)
phosphorylation of PolII is thought to mediate PAF1 recruitment to PolII. The PAF1 complex
may directly stimulate RNA PolII transcription or act synergistically with other factors to
promote transcriptional elongation (Jaehning et al., 2010). During transcriptional elongation, the
PAF1 complex may recruit the histone methyltransferase Set2 to induce trimethylation of H3K36
and the ATPase Chd1 to remodel chromatin structure (Tomson and Arndt, 2013). In yeast, the
PAF1 complex also promotes H2B K123 monoubiquitylation by recruiting the ubiquitin-ligase
Rad6-Bre1. The H2B moniubiquitination facilitates dimethylation and trimethylation of H3K4
and H3K79 by the histone methyltransferases Set1 and Dot1 (Tomson & Arndt, 2013; Wood et
al., 2003). Recent studies have shown that PAF1 may also regulate promoter-proximal pausing
of PolII (Chen et al., 2015). PAF1 regulates PolII pausing approximately 50 nucleotides
downstream of the transcription start site (TSS) where significant PolII occupancy is found.
Upon PAF1 knockdown, PolII is released to the gene body (Chen et al., 2015). Together, these
studies indicate the PAF1 complex regulates multiple aspects of transcription. By interacting
with the PAF1 complex, PHF6 is thus poised to influence transcription.
PHF6 also interacts with the nucleosome remodeling and deacetylation (NuRD)
chromatin remodeling complex (Todd and Picketts, 2012). The NuRD complex is composed of
the histone deacetylase Hdac1 or Hdac2 and ATPase Chd3 or Chd4, with combinatorial
assembly of other subunits, including histone-binding protein RbAp46 and RbAp48, scaffold
protein Mta1/2, DNA-binding protein Mbd3, and GATA zinc finger domain-containing protein
2A Gatad2a and Gatad2b (Zhang et al., 1998, 1999). The NuRD complex has been widely
studied in cancer and embryonic stem (ES) cells (Lai and Wade, 2011). In acute promyelocytic
9

leukemia (APL), the NuRD complex alters DNA methylation levels leading to gene repression.
Upon removing the NuRD subunit Mbd3 in leukemia cells, DNA methylation levels at the
RARb2 gene are significantly reduced (Morey et al., 2008). In addition, depletion of Mbd3
allows reprogramming of somatic cells to induced pluripotent stem (iPS) cells (Rais et al., 2013).
The Mbd3-NuRD complex is thought to be recruited to the OSKM (Oct4, Sox2, Klf4, and Myc)
target genes and inhibit robust reprogramming. Upon Mbd3 depletion, OSKM proteins interact
with other pluoripotency-inducing chromatin regulators to drive efficient reprogramming (Rais et
al., 2013). Recently, two de novo mutations in the NuRD subunit Gatad2a have been described in
patients with severe intellectual disability (Willemsen et al., 2013), suggesting that the NuRD
complex plays a critical role in brain development.
The NuRD complex is highly expressed in the developing brain. Recent studies by
Yamada, Yang et al. have identified a novel function for the NuRD complex in neuronal
connectivity in the brain (Yamada et al., 2014). The NuRD complex decommissions a subset of
gene promoters by removing H3K9/14 acetylation marks and thereby represses the expression of
developmentally regulated genes to trigger granule neuron parallel fiber/Purkinje cell synaptic
connectivity in the mammalian brain. Upon depletion of Chd4, the core ATPase subunit of the
NuRD complex, these developmental genes are derepressed, leading to defects in granule neuron
presynaptic bouton formation (Yamada et al., 2014). Whether the interaction of PHF6 with the
NuRD complex influences gene expression and establishment of neuronal connectivity remains
unexplored.
PHF6 also interacts with the nucleolar transcription factor upstream binding factor (UBF)
in cells (Wang et al., 2013). UBF recruits RNA polymerase I to rDNA promoter regions. Upon
PHF6 depletion, HeLa cells arrest at the G2/M phase of the cell cycle and have increased levels
of UBF and ribosomal RNA synthesis. PHF6 interacts with UBF and is recruited to rDNA
promoters to repress rDNA expression. Knockdown of PHF6 derepresses the rDNA promoter,
leading to increased ribosomal RNA levels (Wang et al., 2013). However, the mechanism of
rDNA repression by the PHF6-UBF interaction localized to the rDNA promoter remains unclear.
10

In situ RNA hybridization and expression analyses have shown that PHF6 is highly
expressed in the developing central nervous system (CNS) and declines along the course of
development (Voss et al., 2007). These observations suggest that PHF6 expression is tightly
regulated during brain development. Recent studies by Franzoni et al provide insights into the
mechanisms underlying the regulation of PHF6 expression (Franzoni et al., 2015).
Downregulation of PHF6 expression is correlated with an increase in the expression levels of
miR-128, suggesting that miR-128 may regulate PHF6 expression during brain development.
Consistent with this interpretation, expression of miR-128 in cortical neurons triggers the
downregulation of PHF6, an effect that is mediated by miR-128 binding sites within the 3’UTR
of PHF6 mRNA (Franzoni et al., 2015). A prediction of these results is that miR-128 might
influence neuronal migration in the cerebral cortex. Consistent with this prediction, expression of
miR-128 by in utero electroporation in the mouse brain arrests the migration of cortical neurons
in layers III and IV-VI (Franzoni et al., 2015), which phenocopies the migration defects observed
upon PHF6 knockdown (Zhang et al., 2013). Importantly, expression of PHF6 reverses the miR128-induced migration defects (Franzoni et al., 2015), suggesting that PHF6 operates
downstream of miR-128 in the regulation of cortical migration. Whether miR-128 regulation of
PHF6 expression influences other aspects of brain development remains to be explored.
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PHF6 in BFLS Pathogenesis
Identification of a critical role for PHF6 in radial neuronal migration in the cerebral
cortex raises the important question of whether deregulation of PHF6 function in migration
contributes to BFLS pathogenesis. Proper migration and positioning of neurons is a prerequisite
for correct neuronal connectivity (Ayala et al., 2007; Morgan-Smith et al., 2014; Nadarajah &
Parnavelas, 2002). Radially migrating neurons in the cerebral cortex are born in the ventricular
zone (VZ) and sub-ventricular zone (SVZ), migrate along the radial glia scaffold to reach the
cortical plate (Ayala et al., 2007; Kriegstein & Noctor, 2004; Vaillend et al., 2008). The oldest
neurons reside in the deep layer of the cortical plate, and newly generated neurons pass the deep
layers to reside in more superficial layers (Greig et al., 2013). Upon PHF6 knockdown, neurons
arrest in the intermediate zone, and the ectopic cells have neuronal hyperexcitability (Zhang et
al., 2013). Introduction of an RNAi-resistant form of wild type-PHF6 into PHF6 knockdown
mice rescues the migration defects, suggesting that the RNAi-induced phenotype is the result of
specific knockdown of PHF6 rather than off target effects (Zhang et al., 2013). In vivo structurefunction analyses of PHF6 demonstrate that BFLS patient-specific mutations impair the ability of
PHF6 to promote neuronal migration (Zhang et al., 2013). Strikingly, neuropathological studies
performed in the first identified BFLS patient have revealed defects of neuronal migration in the
cortical plate including coarse gyri, cortical dysplasia with indistinct lamination and heterotopic
neurons observed in the subcortical white matter (Brun et al., 1974).
PHF6 knockdown in the mouse cerebral cortex also triggers the formation of white
matter heterotopias with aberrant neuronal activity (Zhang et al., 2013). Importantly,
electrophysiological recordings reveal significant hyperexcitability of heterotopic neurons.
Whole-cell patch clamp recordings reveal an aberrant pattern of activity in heterotopic neurons
in PHF6 knockdown animals (Zhang et al., 2013). The membrane potential of heterotopic
neurons oscillates, leading to frequent firing of action potentials. Further, knockdown of
Neuroglycan C, a PHF6 target gene, also leads to formation of heterotopias that harbor neuronal
hyperexcitability (Zhang et al., 2013). Heterotopias have been postulated to contribute to seizure
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susceptibility (Ackman et al., 2009). Heterotopias may serve as loci that initiate seizure activity.
Studies in both genetically induced animal models and depth electrode recordings from patients
have suggested that heterotopic loci may function to generate epilepsy (Aghakhani et al., 2005;
Kothare et al., 1998, Manent et al., 2009). Together, these data suggest that inhibition of the
PHF6 pathway triggers the formation of heterotopias in which neurons are hyperexcitable. These
findings may be relevant to reduced seizure threshold in BFLS patients.
Although recent studies of PHF6 function have focused on its role in the regulation of
neuronal migration and positioning in the cerebral cortex, it is likely that PHF6 has additional
functions in the developing brain owing to its expression pattern (Voss et al., 2007; Zhang et al.,
2013). PHF6 is expressed throughout the cerebral cortex and although levels of PHF6 drop with
maturation, PHF6 is poised to regulate other aspects of neuronal development beyond neuronal
positioning. In addition, PHF6 may have developmental roles outside of the cerebral cortex that
may be relevant to BFLS pathogenesis.
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Perspectives
Recent studies have advanced our understanding of the underlying molecular
mechanisms of PHF6 function and its relevance to BFLS pathogenesis. These studies suggest
that PHF6 is required for proper neuronal migration and that deregulation of PHF6 function in
neuronal positioning contributes to the pathogenesis of BFLS. Analyses of PHF6 signaling in
cells, primary neurons, and in the developing mouse brain suggest a role for PHF6 in
transcription. Although progress has been made, further research is required to gain a better
understanding of PHF6 functions in brain development and pathogenic mechanisms underlying
BFLS.
The finding that migration arrest in the PHF6 knockdown animals leads to the formation
of heterotopias has important implications in the pathogenesis of BFLS. Clinically, heterotopia
formation is associated with epileptic activity in the brain, which has been documented in BFLS
patients (Robinson et al., 1983). Additionally, heterotopic neurons are hyperexcitable (Ackman
et al., 2009). In neuropathological studies, in addition to evidence of whiter matter heterotopias,
the cerebral cortex displays cortical dysplasia with indistinct or absent lamination (Brun et al.,
1974). Whether cortical dysplasia due to impairment of PHF6 function is relevant to BFLS
requires further study.
The identification of a novel transcriptional PHF6/PAF1 pathway in the developing brain
has opened new avenues for the study of the molecular mechanisms that underlie XLID, and has
also brought new insights into the regulation of transcription. The association of PHF6 with the
PAF1 complex suggests an important role for PHF6 in the regulation of transcriptional
elongation during neuronal development. Intriguingly, nascent transcriptional initiation is widespread across the genome, and the transition from transcriptional initiation to elongation
represents a critical step of gene regulation (Guenther et al., 2007; Krumm et al., 1995; Muse et
al., 2007; Nechaev & Adelman, 2012). Previous studies have revealed that the PAF1 complex
cooperates with DSIF and the elongation factor SII/TFIIS, and thereby promotes elongation of
PolII along the gene body (Chen et al., 2009; Zhu et al., 2005). In view of the findings that PHF6
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may function to negatively or positively regulate gene expression (Todd & Picketts, 2012; Wang
et al., 2013; Zhang et al., 2013) and PAF1’s critical role in gene pausing (Chen et al., 2015), it
would be interesting to investigate whether PHF6 regulates gene pausing, pause release, or both.
The PAF1 complex appears to be critical for histone modifications including H3K4 trimethylation (H3K4me3) or histone H2B (ubH2B) ubiquitination (Krogan et al., 2003; Wood et
al., 2003). Whether PHF6 promotes modifications of histones via interactions with the PAF1
complex remains an open question.
The identification of Neuroglycan C as a target gene of PHF6 and the PAF1 complex
provides new insights in neuronal migration and intellectual disability (Zhang et al., 2013). The
Neuroglycan C gene, a member of the neuregulin family, encodes a transmembrane chondroitin
sulfate glycoprotein, which has been implicated in the regulation of cortical radial migration
(Anton et al., 1997; Brandt et al., 2007; Kinugasa et al., 2004; Rio et al., 1997). The Neuroglycan
C gene might represent a locus associated with schizophrenia, a neuropsychiatric disorder in
which impaired neuronal migration may play a pathogenic role (Impagnatiello et al., 1998; Lee
et al., 2011; So et al., 2010; Tomita et al., 2011). These observations raise the possibility that
mutations of PHF6 may contribute to the pathogenesis of neuropsychiatric disorders beyond
intellectual disability. It will be also interesting to determine whether deregulation of
Neuroglycan C might play a role in intellectual disability and epilepsy.
Beyond the role of the PHF6-PAF1 interaction in neuronal positioning, it will be
important to characterize the significance of the PHF6 interaction with the NuRD complex in
brain development. Recently, two de novo mutations in the NuRD subunit Gatad2a have been
reported in patients with severe intellectual disability (Willemsen et al., 2013). The NuRD
complex represses transcription of developmentally regulated genes and thereby drives
synaptogenesis in the mammalian brain (Yamada et al., 2014). Whether the NuRD complex
regulates neuronal migration in the cerebral cortex remains unclear. In granule neurons of the
cerebellum, the NuRD complex removes H3K9/14 acetylation marks at a subset of genes during
development to drive synaptogenesis (Yamada et al., 2014). However, how the NuRD complex
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and PHF6 might regulate the epigenetic landscape of the genome in the cerebral cortex remains
unknown.
Identification of the PHF6/UBF interaction in HeLa cells suggests that PHF6 may
function in the nucleolus to regulate rDNA transcription (Wang et al., 2013). The nucleolus is a
prominent subnuclear domain implicated in ribosomal RNA (rRNA) transcription, which
accounts for up to 80% of RNA synthesis in eukaryotic cells (Nemeth and Langst, 2011).
Transcription of rDNA is essential during the cell cycle (Roussel et al., 1996); however, its
importance in post-mitotic neurons remains to be elucidated. Recently, intellectual disabilitylinked proteins including FMRP and the RNA methyltransferase NSUN2 have been shown to be
transported to nucleoli (Khan et al., 2012; Nemeth and Langst, 2011). Whether PHF6 may harbor
regulatory roles in the nucleolus has been unexplored.
Future studies of PHF6 should focus on elucidation of the biochemical functions of PHF6
including the role of its PHD domains. In addition, it will be important to explore whether PHF6
harbors additional biological functions in brain development including neural progenitor
proliferation, differentiation, synaptic development and circuit integration, and determine
whether deregulation of such functions contributes to the pathogenesis of BFLS.

16

Figure 1. PHF6 gene with patient mutations. The small blocks in light purple represent the 3’
and 5’ UTR of PHF6 gene. The blocks in dark purple represent the coding exons with PHD
domains shown in pink. Point mutations in BFLS are shown as red dots. Five large domain
deletions in BFLS are also shown.

Figure 2. A proposed model for PHF6-PAF1 complex in regulation of neuronal migration during
cortical development. During critical period of neuronal migration, PHF6 interacts with PAF1
transcriptional elongation complex to regulate downstream targets including Neuroglycan C to
regulate neuronal migration and positioning.
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Table1. Summary of PHF6 mutations in BFLS patients in different individuals from different families.
Mutation
Ref
Amino
Reported clinical
F/
Nucleotide
Acid
features
M
Missense
M

c. 2T>C

p.M1T
Missense

Classical features of
BFLS with no detailed
clinical records.
Classical features of
BFLS.
Born at term after
uneventful pregnancy,
delayed early milestones,
walked at age 4, began
saying a few words at age
5, height of 140cm (<3rd
centile), weight of 45kg
(5th centile), and occipitalfrontal head
circumference of 53.3cm
(10th-25th centile) at age
15, short stature,
triangular face,
hyperplastic supraorbital
digits, deep-set eyes, large
ears, gynecomastia, lower
abdominal obesity, and
small penis and testes
with no evidence of
pubertal change.
Classical features of
BFLS with no detailed
clinical records.

(Lower et al., 2002)

(Crawford et al., 2006)

M

c. 2T>C

p.M1T

c.134G>A

p.C45Y
(familial
)

Missense

M

p.C45Y

Missense

Classical features of
BFLS with no detailed
clinical records.

(Lower et al., 2002)

Missense

Classical features of
BFLS.

(Mangelsdorf et al.,
2009)

M

M

c.134G>A

c.266G>T

(de
novo)

p.G89Y

At age 22, height 173cm,
weight 108kg, head
circumference 61cm.
Moderate intellectual
disability; delayed
development, good
tempered with occasional
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(Lower et al., 2002)

aggressive attacks, no
epileptic seizures.
Brother has similar
symptoms with severe
intellectual disability,
Female carrier in the
family has shown mild
intellectual disability.
Missense

M

c.296G>T

M

M

M

c.686A>G

c.700A>G

c.769A>G

Missense

Classical features of
BFLS with no detailed
clinical records.

(Lower et al., 2002)

Missense

Classical features of
BFLS with no detailed
clinical records.

(Lower et al., 2002)

Missense

Classical features of
BFLS with no detailed
clinical records.

(Lower et al., 2002)

Missense

Classical features of
BFLS.

(Vallée et al., 2004)

p.H229
R

p.K234
E

p.R257
G

c.769A>G

p.R257
G

(Lower et al., 2002)

Female carrier has mild
clinical features of BFLS
including obesity, large
ears, amenorrhea,
hypothyroidism, epilepsy,
and learning difficulties.

p.C99F
M,
F

Classical features of
BFLS.

Severe intellectual
disability, self-injurious
behavior, stooped
hyposcoliotic posture,
central obesity, marked
gynecomastia,
hypogonadism, and hand
and feet anomalies.
Hodgkin's lymphoma
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(Carter et al., 2009)

Missense

M

c.940A>G

F

c.22A>T

At age 18, height 171.5
cm, head circumference
55.7cm, moderate obesity,
marked gynecomastia,
limbs showing
hypermobility.
Nonsense

Classical features of
BFLS.

(Lower et al., 2002)

Nonsense

Classical features of
BFLS.

(Zweier et al., 2013b)

p.K8X

Head circumference 34cm
(-0.5SD), delayed walking
at age 2.5. During first
years, frontotemporal
alopecia, nystagmus,
strabismus, small teeth,
hypoplastic labia minora
and clitoris.

c.955C>T

At age 6, head
circumference of 49cm (1.63SD), moderate to
severe intellectual
disability, lack of
swallowing coordination,
sociable and happy, facial
dimorphism, and tapering
fingers. Normal MRI.

p.R319
X
M

c.1024C>T
(original

(Crawford et al., 2006)

Psychomotor
developmental delay,
language delay, mild
intellectual disability (IQ
of 61) and lack of
inhibition in sexual
contacts.

p.I314V
M

Classical features of
BFLS.

p.R342
X

Nonsense

Classical features of
BFLS.
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(Gécz et al., 2006;
Lower et al., 2004)

family)

Developmental delay,
upslanting palpebral
fissures, large ears, a high
palate, hypotonia,
cryptorchidism, and an
inguinal hernia.
At age 15, talk sentances
consisting of three or four
words, short stature and
obesity, large ears,
protruding cheeks,.
Female carrier is clumsy
when running/jumping,
but has normal cognitive
function. Big hands, ears
and feet, with some
sensory impairment in the
legs. Normal MRI.
Nonsense

M

c.1024C>T

p.R342
X

Delayed developmental
milestones, height on 25th
centile, weight over 97th
centile, head
circumference over 98th
centile, narrow bitemporal
diameter, upslanting eyes,
prominent supraorbiral
ridges, hypotelorism, long
ears/earlobes, a prominent
chin, obese, marked
gynecomastia, a
hypoplastic scrotum with
retractile testes, cubitus
valgus, tapered fingers.

Female carrier is obese,
has deep-set eyes,
prominent supraorbital
ridges, large ear lobes,
tapered fingers, broad feet
and short toes.
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(Lower et al., 2002)

M

c.1024C>T

p.R342
X

Nonsense

Classical features of
BFLS.

(Lower et al., 2002)

M

c.1024C>T

p.R342
X

Nonsense

Classical features of
BFLS.

(Crawford et al., 2006)

M

c.1024C>T

p.R342
X

Nonsense

Classical features of
BFLS.

(Crawford et al., 2006)

Nonsense

Classical features of
BFLS and T cell acute
lymphoblastic leukemia at
age 9

(Chao et al., 2010)

Frameshift

Classical features of
BFLS.

(Crawford et al., 2006)

M

F

c.1024C>T

p.R342
X

Poor coordination,
delayed speech, normal
IQ of 87, high level of
thyroid stimulating
hormone, low level of
thyroxin at age 7-8; at age
14, height 180cm, weight
115 kg, shallow forehead,
fleshy earlobes, deep set
eyes, broad feet,
hammertoes, no
menstruation at age 14,
tactile defensive and
emotionally labile, poor
spatial awareness, and
startles to noise.

c.27dupA

p.G10fs
X21

M

IVS28A>G

Frameshift

Classical features of
BFLS with mild to
moderate intellectual
disability, and global
developmental delay.

(Vallée et al., 2004)

Frameshift

Classical features of
BFLS

(Wieczorek et al.,
2013; Zweier et al.,
2013b)

M46fsD
exon3

F

c.677delG

p.
G226fs
E53

Diagnosed with Coffin
Siris Syndrome in early
infancy. At 9 years old,
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height 1.7SD, weight
30kg, head circumference
54cm (1.4SD). Mild
intellectual disability, shy
and intolerance for being
alone, sleeping
difficulties, mild
clinodactyly, short toes,
and facial dysmorphism.

F

Missense

Classical features of
BFLS, previously
diagnosed with Coffin
Siris Syndrome, unstable
gait on stairs, head
circumference of-1.0SD
at age 11, aggressive
behavior, susceptibility to
urinary tract infections,
frequent constipation,
facial dysmorphism, and
tapered fingers.

(Wieczorek et al.,
2013; Zweier et al.,
2013b)

Duplication

Classical features of
BFLS, delayed
milestones, unstable gait,
delayed speech,
conductive hearing loss,
potential retinal
dystrophy, and seizures at
age 20. At age 22, head
circumference 56.5(1.4
SD), facial dysmorphism,
tapering fingers.
Behavioral problems
including short attention
span, hyperactivity,
compulsive behavior,
sleeping difficulties, and
lack of emotional
detachment.

(Zweier et al., 2013b)

Duplication

Classical features of
BFLS.

(Zweier et al., 2013b)

c.914G>T

p.
C305F

F

Dosage
gain of
exon 4,
5
F

Dosage
gain of
exon 4,
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5

Head circumference of
34cm (1.4 SD) at birth;
At age 3-4 month, several
single seizures, delayed
walking and language,
sociable behavior,
constipation, and
neurogenic bladder. At
age 32, head
circumference 54cm (-0.3
SD).
Deletion

Affectin
g exon
4, 5
Deletion

Classical features of
BFLS. Delayed
developmental milestone,
feeding difficulties,
muscular hypotonia,
single horseshoe kidney,
obstructive uropathy,
recurrent pyelonephritis,
and multiple febrile
seizures.

(Di Donato et al.,
2014)

Deletion

Classical features of
BFLS with mild
intellectual disability.

(Berland et al., 2011)

F

100kb
deletion

Deletion
of last 5
coding
exons

At age 7, mild hearing
loss, and recurrent middle
ear infections;

F

15kb
deletion

Deletion
of last 3
exons

(Zweier et al., 2013b)

Head circumference 53cm
(2.2SD), linear skin
hyperpigmentation,
sociable behavior, and
facial dimorphism.

F

6kb
deletion

Classical features of
BFLS with moderate
intellectual disability.

At age 16, head
circumference 56.6cm
(75th centile), slightly
widened ventricles and
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increased white matter
signal abnormality on
MRI.

M

c.999-1001
delTGA

Deletion

Classical features of
BFLS with delayed
milestones.

(Baumstark et al.,
2003)

Deletion

First patient description.

(Börjeson et al., 1962;
Gécz et al., 2006)

p.D333d
el

Delayed milestones,
severe mental deficiency
with IQ of 20, seizures,
hyperactive and
aggressive behaviors,
large ears, short stature,
small genitalia, and small
pituitary gland. Coarse
gyri, widened ventricular
system, cortical dysplasia
with indistinct lamination,
and heterotopias.

M

c.999-1001
delTGA

p.D333d
el
Deletion

Entire gene
deleted
Deletion

270kb
deletion

(Zweier et al., 2013)

Sleeping difficulties,
compulsive eating
behavior, muscular
hypotonia, ectopic left
kidney, strabismus,
hyperopia, bilateral
sensorineural hearing
loss, enlarged ventricles
on MRI.

F

F

Classical features of
BFLS. Head
circumference 35.5
(0.5SD) at birth, delayed
motor milestones and
facial dysmorphism.

Classical features of
BFLS. Mild muscular
hypotonia, mild speech
delay, narrow external
auditory canal, mild
learning disability; IQ
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(Di Donato et al.,
2014)

Tab
le1.
Su
mm
ary of PHF6 mutations in BFLS patients in different individuals from different families. Classical features
of BFLS includes mild to severe mental retardation, hypogonadism, hypometabolism, obesity with
marked gynecomastia, facial dysmorphism, narrow palpebral fissure, large and fleshy ears, tapered
fingers.
within borderline to
normal range.
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ABSTRACT
Mutations of the transcriptional regulator PHF6 cause the X-linked intellectual disability
disorder Börjeson-Forssman-Lehmann syndrome (BFLS), characterized by cognitive
impairment, developmental delay and seizures. However, the mechanisms by which mutations of
PHF6 contribute to the pathogenesis of BFLS remain poorly understood. Here, we report the
first mouse model of BFLS. Using a CRISPR-Cas9 approach, we have generated mice in which
Cysteine 99 within the PHD domain of PHF6 is replaced with phenylalanine (C99F). Mice
harboring the patient-specific PHF6 C99F mutation display deficits in cognitive functions,
emotionality, and social behavior as well as reduced threshold to seizures. Electrophysiological
studies reveal that the intrinsic excitability of entorhinal cortical stellate neurons is increased,
providing a cellular basis for seizure predisposition upon PHF6 deficiency. Our findings advance
our understanding of the mechanisms underlying BFLS pathogenesis.

29

INTRODUCTION
Intellectual disability (ID) is a prevalent developmental disorder that affects 1% to 3% of
the general population (Bhasin et al., 2006). With no effective treatments, ID poses enormous
economic costs to society. There is thus an urgent need to better understand the pathogenesis of
ID. Human genetics studies have uncovered a number of gene mutations associated with ID.
However, although a few genetic causes of ID such as fragile X and Rett syndrome have been
the subject of intense scrutiny (Amir et al., 1999; Verkerk et al., 1991), the functions of most ID
proteins and the mechanisms by which these proteins regulate pathologically relevant biological
processes remain poorly understood.
Börjeson-Forssman-Lehman syndrome (BFLS) was identified over five decades ago as
an X-linked syndrome of moderate to severe impaired cognitive function associated with
developmental delay, truncal obesity, and seizures (Börjeson et al., 1962; Gécz et al., 2006;
Lower et al., 2002). Forty years later, mutations in the gene encoding the PHD and zinc finger
domain-containing protein PHF6 were identified as the genetic cause of BFLS (Lower et al.,
2002). Since then, multiple mutations in distinct regions of PHF6 including within its two PHD
domains have been identified in BFLS patients (reviewed in Jahani-Asl et al., 2016). However,
how PHF6 mutations trigger the pathogenesis of BFLS remains to be elucidated. Modeling of
cognitive disorders such as fragile X and Rett syndromes in mice has helped to advance our
understanding of these disorders (Guy et al., 2001; Irwin et al., 2000). However, a mouse model
of BFLS using patient-specific PHF6 mutations has yet to be established.
In this study, we report the first patient-specific PHF6 mutant mouse model of BFLS.
Using a CRISPR-Cas9 approach, we have generated mice in which Cysteine 99 within the PHD
domain of PHF6 is replaced with phenylalanine (C99F). Mice with the patient-specific PHF6
C99F mutation display deficits in cognitive functions, emotionality and social behaviors, and are
more susceptible to seizures, suggesting that PHF6 C99F mice feature phenotypes relevant to
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BFLS. In electrophysiological studies in acute slices, the intrinsic excitability of entorhinal
cortical layer II stellate neurons is increased, providing a cellular basis for susceptibility of BFLS
mice to seizures. Collectively, our findings broaden our understanding of the cellular
underpinnings of BFLS pathogenesis.
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RESULTS
Generation of patient-specific PHF6 mutant mouse model of BFLS
We reasoned that generating a patient-specific knock-in mutation of PHF6 in mice would
provide a useful tool in studies of BFLS pathogenesis. We first characterized the expression of
different patient-specific mutations of PHF6 in cells. Among patient-specific mutations of PHF6,
three mutations led to substantial reduction of PHF6 protein levels (Figure 3a), suggesting that
BFLS may result from hypomorphic PHF6 function. Among the three mutations, substitution of
cysteine 99 with phenylalanine (C99F), located in the first PHD domain of PHF6, dramatically
reduced the levels of PHF6 protein (Figure 3a).
We next generated C99F knock-in mice. Using a CRISPR-Cas9 method. The single
nucleotide mutation nt.296G>T was successfully introduced in the mouse PHF6 gene, confirmed
with Sanger sequencing (Figure 3b, S1a). PHF6 C99F mice were backcrossed to mice with
C57B6 background for more than ten generations. Screening of potential CRISPR-Cas9 offtarget sites in the mouse genome predicted by COSMID (Cradick et al., 2014) and CRISPOR
(Haeussler et al., 2016) revealed no mutations. Genomic sequences in the ~1kb regions flanking
the C99F point mutation were also intact (Figure S1a). PHF6 C99F knock-in mice were born
with Mendelian ratio, had slightly reduced body weight, length, body surface area and survived
to adulthood (Figure S1d-g). Notably, morphological analyses of PHF6 C99F and control
littermate mice showed little or no differences in body mass index (BMI), ear length, facial
length, interocular distance and testis weight when normalized to body weight (Figure S1h-l).
These data suggest that PHF6 C99F mice do not phenocopy syndromic features of BFLS
patients.
Having generated the PHF6 C99F knock-in mouse, we characterized the expression of
PHF6 in the cerebral cortex in these mice. As expected, immunoblotting analyses in control mice
revealed PHF6 was expressed in the mouse cerebral cortex at early embryonic ages, and was
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substantially downregulated postnatally (Figure 3c) (Zhang et al., 2013). In
immunohistochemical analyses, PHF6 co-localized with the layer V marker Ctip2 in the cortical
plate of control mice at embryonic day 14 (E14), and was expressed in all layers of the cortical
plate at E18 (Figure 3d). Strikingly, the levels of PHF6 protein were substantially reduced,
though not eliminated, in the cerebral cortex in PHF6 C99F mice at E14.5 and P0 (Figure 3e-g,
S1c). However, the levels of PHF6 mRNA in the cerebral cortex in the C99F mice were not
reduced (Figure 3f), suggesting that the stability of PHF6 protein in C99F mice may be reduced.

PHF6 C99F knock-in mice display impairments in cognition, social interaction and
emotionality
We conducted behavioral analyses on PHF6 C99F mice in a battery of tests to assess
locomotor activity, sensorimotor function, spatial learning/memory, fear conditioning, social
interaction and startle response. In analyses of contextual fear conditioning data, PHF6 C99F
mice exhibited significantly reduced freezing levels compared with control littermate animals on
day 2 (Figure 4a), suggesting that learning is impaired in PHF6 C99F mice to associate the
contextual cues present in the chamber with the foot shock. Importantly, no differences were
observed between groups during either the baseline period or during tone-shock training on day 1
(Figure S2a). Also, the groups did not differ during the altered context baseline on day 3,
although moderate performance deficits were observed in the PHF6 C99F mice during the
auditory cue test on day 3 (Figure S2a). The performance difference between the groups of mice
in contextual fear responses were not due to alterations in shock sensitivity of (data not shown).
Defects in contextual fear memory were observed in another independent cohort of mice (Figure
S3a). Mice were also subjected to a novel object-location test to evaluate recognition memory in
mice. We found that control mice, but not PHF6 C99F mice spent more time investigating the
moved object than the stationary object (Figure 4b). In other analyses, PHF6 C99F mice did not
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exhibit performance deficits during the cued, place (Figure S2b), or probe (not shown)
conditions when tested in the Morris water maze (MWM), suggesting that PHF6 C99F mice may
not be impaired in spatial learning acquisition or retention. Together, our data suggest that PHF6
C99F mice have deficits in contextual fear conditioning and in some forms of spatial learning.
To characterize sociability and preference for social novelty, mice were subjected to a
three-chamber social approach task. Both control and PHF6 C99F mice exhibited preference for
investigating a novel stimulus mouse versus an empty withholding cage (data not shown).
However, control littermate mice, but not PHF6 C99F mice, showed a preference for a novel
mouse compared to a familiar (cagemate) mouse (Figure 4c, S3b). A similar preference for the
novel mouse in control but not PHF6 C99F mice was observed in an independent cohort (Figure
S3c, d). Together, these data suggest that PHF6 C99F mice display normal levels of sociability,
but may be impaired in social recognition memory.
Ambulatory activity and exploratory behavior during a control 1-h locomotor activity test
prior to the conditioned fear procedure revealed reduced activity in PHF6 C99F mice, but only in
latter part of the test session (Figure 4d). Vertical rearing frequency was also significantly
reduced in PHF6 C99F mice (Figure 4e). Similar effects of the PHF6 C99F mutation on
ambulatory activity and vertical rearing were observed in an independent cohort (Fig. S3e-f).
These results suggest that PHF6 C99F mice may show reduced levels of attention or interest
toward novel environments, which may also account for reduced investigation time toward the
moved object in the object location test (Figure 4b). In two independent cohorts, PHF6 C99F
mice also exhibited significantly reduced acoustic startle response throughout the test session
(Figure 4f, S3g), although no significant effects were observed on prepulse inhibition (PPI) (not
shown). These data suggest that sensorimotor reactivity was attenuated in PHF6 C99F mice
compared to littermate controls, although sensorimotor gating appeared unaffected in the mutant
mice. Collectively, our data suggest that PHF6 plays critical roles in normal cognitive
development as it relates to certain forms of learning and memory, emotionality and social
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behaviors.

PHF6 C99F mice exhibit increased neuronal excitability and seizure susceptibility
Besides impaired cognitive functions, seizures represent an important aspect of the
clinical presentation of BFLS (Jahani-Asl et al., 2016, Kasper et al., 2017). We therefore
characterized the susceptibility of PHF6 C99F knock-in mice to seizures. We injected PHF6
C99F and control littermate mice intraperitoneally with pentylenetetrazol (PTZ), a GABA
antagonist. PHF6 C99F mice showed reduced time to reach generalized seizures (Figure 5a).
PTZ-induced seizures are rapidly progressing (Zhang and Wong, 2012). We, therefore, used the
glutamate agonist kainic acid to induce slowly progressing seizures, allowing for scoring seizure
stages according to the Racine scale (Racine et al., 1972). PHF6 C99F animals showed more
rapid seizure progression and greater number of seizure events at higher Racine scores (Figure
5b). Together, these results suggest that PHF6 C99F mice phenocopy the predisposition of BFLS
patients to seizures.
We next determined the cellular basis for seizure predisposition in PHF6 C99F mice.
Alterations of neuronal excitability in diverse neuronal populations may be epipeptogenic
(Scharfman, 2007). We focused our analyses on layer II stellate neurons in the entorhinal cortex,
whose excessive activation triggers seizures (Vismer et al., 2015). Current-clamped stellate
neurons in acute brain slices from C99F and control littermate mice were depolarized to a range
of potentials from -55 mV to -44 mV with a 1-mV step via automatic current injection to induce
action potential firing. We observed a large increase in the probability of action potential firing
in stellate neurons in C99F mice. Nearly 40% of all neurons in brain slices of PHF6 C99F mice
fired action potentials at -53 mV compared to none from control mice, and over 90% of all
neurons from C99F mice fired action potentials at -50 mV in contrast with only 15% of control
neurons (Figure 5c). In addition, the number of action potentials fired at -50 mV over a 20 sec
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period was markedly increased in C99F mice (Figures 5d-e). In a standard ramp protocol (Deng
and Klyachko, 2016; Yamada-Hanff and Bean, 2013), action potential threshold of stellate
neurons in C99F mice was significantly decreased (Figure 5f-g). Together, these results suggest
that entorhinal cortical stellate neurons have increased excitability in PHF6 C99F mice.
We next determined the physiological basis for increased neuronal excitability in PHF6
C99F mice. No detectable changes in the resting membrane potential were observed in stellate
neurons of C99F mice (Figure 5h). However, membrane capacitance was significantly decreased
(Figure 5i) and input resistance was significantly increased (Figure 5j) in PHF6 C99F mice
compared to control littermate mice. Input resistance normalized to cell capacitance in each
recorded cell was also significantly increased in C99F mice (Figure 5k), suggesting that
alterations in input resistance occur independently of changes in capacitance. Notably,
two clearly distinguishable subpopulations of stellate neurons were observed in C99F knock-in
mice that stratified according to the cell capacitance (Supplementary Figure S4A; large neurons:
125.4 ± 8.2 pF, n = 8; small neurons: 55.3 ± 5.8 pF, n = 6; P = 0.00003). However, alterations in
input resistance and action potential threshold in C99F knock-in neurons occurred independently
of differences in capacitance (Supplementary Figures S4B-4E). Taken together, our data suggest
that stellate neurons in C99F knock-in mice are hyperexcitable due to, at least in part, deminition
of action potential firing threshold associated with increased input resistance and decreased cell
capacitance. Because stellate neurons represent the major projection neurons to the
hippocampus, our electrophysiological data suggest that hippocampal inputs from the entorhinal
cortex are abnormally hyperexcitable, which may contribute to susceptibility to seizures.Taken
together, our data suggest that stellate neurons in C99F mice are hyperexcitable due to at least in
part diminution of action potential firing threshold associated with increased input resistance and
decreased cell capacitance.
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DISCUSSION
In this study, we report the first mouse model of Börjeson-Forssman-Lehmann syndrome
(BFLS). Mice harboring the patient-specific PHF6 C99F mutation display deficits in cognitive
functions, emotionality, and social behaviors, and are susceptible to seizures, phenocopying key
clinical features of BFLS. Electrophysiological analyses reveal increased excitability of
entorhinal cortical stellate neurons secondary to reduced threshold to action potential firing in
PHF6 C99F mice, providing a cellular basis for seizure predisposition of the brain upon PHF6
deficiency. Gene profiling analyses in PHF6-deficient mice show that PHF6 promotes the
expression of neurogenesis genes and concomitantly suppresses expression of synaptic genes.
PHF6-regulated genes are overrepresented in gene signatures and modules that are deregulated in
the brain of patients with autism spectrum disorder (ASD). Taken together, our findings provide
novel insights into the cellular and molecular underpinnings of BFLS, and may suggest potential
links of BFLS with autism spectrum disorders.
The identification of a novel mouse model of BFLS provides an excellent tool for studies
of the pathogenesis of BFLS. In addition to mild to severe intellectual disability, BFLS patients
display disturbances in adaptive behaviors including aggressive behavior, poor spatial awareness
and short attention span (Crawford et al., 2006; Gécz et al., 2006; Mangelsdorf et al., 2009;
Zweier et al., 2013b). Consistent with the diverse picture of cognitive impairment in BFLS
patients, behavior analyses reveal that PHF6 C99F mice have deficits in multiple domains
including some forms of learning and memory, social interactions, and emotionality.
The identification of increased seizure susceptibility in the C99F mouse sheds light on
the cell types and neural circuits that might contribute to epilepsy in BFLS patients. The finding
of increased excitability associated with reduced action potential and increased input resistance
in entorhinal cortical layer II stellate neurons provides a cellular basis for seizures in BFLS.
Because increased excitation from stellate cells to the hippocampal dentate gyrus is associated
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with temporal lobe epilepsy (Janz et al., 2017), it will be interesting to determine whether BFLS
patients have focal seizures of temporal lobe origin, as suggested by a case of a BFLS patient
with temporal lobe spikes on EEG (Kasper et al., 2017). Notably, layer II stellate neurons project
to the hippocampus via the perforant pathway, which plays a critical role in contextual fear
memory and object location recognition (Kitamura et al., 2015; Tennant et al., 2018). Thus,
electrophysiological abnormalities of stellate neurons may also contribute to defects in spatial
recognition and contextual fear memory in PHF6 C99F knock-in mice. Beyond neurons in the
entorhinal cortex, it will be important in future studies to explore the role of other populations of
neurons and their networks in the pathogenesis of epilepsy in BFLS.
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Figure 3. Generation of patient-specific PHF6 mutant mouse model of BFLS.
(a) (Top) Schematic of PHF6 is shown with patient-specific mutations in BFLS labeled with
asterisks. Green indicates nuclear localization sequence; blue indicates nucleolar localization
sequence. (Bottom) Lysates of 293T cells transfected with expression plasmids encoding FLAG
and HA-tagged PHF6, the control vector or patient specific mutations of PHF6 were subjected to
immunoblotting with the Flag antibody and an antibody to 14-3-3β, the latter serving as loading
control.
(b) Sequencing traces of the wildtype and C99F PHF6 alleles.
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(c) Lysates of the mouse cerebral cortex at embryonic day 14 (E14), E18, postnatal day 2 (P2)
and P6 were subjected to immunoblotting with the PHF6 and 14-3-3β antibodies, the latter
serving as loading control. PHF6 was highly expressed at E14 to E18, and declined postnatally.
(d) Sections of the cerebral cortex from mice at E14, E18, P2 and P6 were subjected to
immunohistochemistry using the PHF6 antibody alone (left) or together with the CTIP2
antibody, which labels layer V/VI neurons, and the DNA dye bisbenzimide (Hoechst) (right).
PHF6 was co-localized with CTIP2 at E14, and was ubiquitously expressed in all cortical layers
at E18. Scale bar = 50 um
(e) Lysates of the cererbral cortex from control male, C99F male, and C99F heterozygote female
mice were subjected to immunoblotting with the PHF6 and 14-3-3β antibodies. Levels of PHF6
protein were reduced in the cortex of male C99F mice.
(f) The levels of PHF6 mRNA in the cerebral cortex of control and C99F mice in RNA-seq
analysis (n = 5) were not different. Data are presented as mean ± SEM.
(g) Sections of the cerebral cortex from E14.5 control and C99F mice were subjected to
immunohistochemistry analyses using the PHF6 antibody and the DNA dye bisbenzimide
(Hoechst). PHF6 expression was reduced in the cortical plate in C99F mice. Scale bar = 50 um.
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Figure 4. PHF6 C99F knock-in mice exhibit deficits in cognition, social interaction and
emotionality.
(a) C99F mice (n = 12) and control littermates (n = 12) were evaluated on a contextual fear
conditioning test where the C99F group exhibited significantly reduced freezing levels.
(b) Performance of control (n = 11) and PHF6 C99F knock-in mice (n = 11) was assessed on a
novel object-location test. Control, but not C99F knock-in mice spent more time investigating
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the object moved to a novel location.
(c) Sociability and preference for social novelty were evaluated in control (n = 12) and PHF6
C99F knock-in mice (n = 12) using the three- chambered social approach test. Control but not
C99F mice spent more time investigating the novel mouse than cagemate mouse.
(d) PHF6 C99F knock-in mice (n = 12) displayed reduced ambulations compared to control (n =
12) in the 1-hour locomotor activity test.
(e) PHF6 C99F knock-in mice (n = 12) displayed reduced vertical rearing frequency compared to
control (n = 12) in the 1-hour locomotor activity test.
(f) C99F knock-in mice (n = 12) displayed significantly reduced acoustic startle magnitudes
compared to control littermate animals (n = 12).
*p<0.05, **p<0.01, ****p<0.0001 two-way repeated measure ANOVA, followed by pair-wise
comparisons that were Bonferroni adjusted.
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Figure 5. PHF6 C99F knock-in mice exhibit seizure susceptibility and increased neuronal
excitability.
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(a) Control littermate (n = 18) and PHF6 C99F knock-in mice (n = 17) were subjected to PTZinduced seizures. Time to reach generalized seizure was recorded. PHF6 C99F knock-in mice
showed reduced time to reach generalized seizure, unpaired t-test, *p<0.05.
(b) Control littermate (n = 7) and PHF6 C99F knock-in mice (n = 8) were subjected to seizure
induction by kainic acid followed by Racine scale scoring of animal behavior every 5min for
100mins. PHF6 C99F knock-in mice reached higher Racine stage than control mice at earlier
time points. Two-way repeated measure ANOVA, *p<0.05
(c) Current-clamped layer II stellate cells in acute slices of the entorhinal cortex were
depolarized to different potentials (from -55 to -44 mV with a step of 1 mV) via automatic
current injection to induce action potential (AP) firing. Stellate neurons in C99F knock-in mice
had higher firing probability compared to control cells * p<0.05, ** p<0.01, Chi-square test
within corresponding potentials.
(d) Sample traces of spontaneous AP firing recorded at -50 mV in control and C99F cells.
(e) AP firing rate was measured as a number of AP fired over a 20sec period. C99F cells had
increased AP firing rate. *p<0.05, t-test.
(f) APs were evoked by a ramp current injection (0.15 pA/ms, lower traces). Representative AP
traces are shown (upper traces). Only the first AP was used to estimate the AP threshold
(arrows).
(g) Summary of the data in (f) reveated that AP threshold is decreased in C99F mice. C99F cells
had reduced AP threshold. **p<0.01, t-test.
(h) Average rest membrane potential (RMP) in control and C99F cells were not different.
(i) Membrane capacitance in C99F cells were reduced compared to control cells.
(j) Input resistance in C99F cells were increased compared to control cells.
(k) Capacitance-normalized input resistance in C99F cells were increased compared to control
cells.
**p<0.01, t-test. Unless specified, data are presented as mean ± SEM.
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Supplemental Figures

Figure S1. Validation of PHF6 C99F knock-in mice.
(a) Schematics of PHF6 C99F knock-in mouse generation using CRISPR-Cas9 technology. Primers labeled in
yellow were used for Sanger sequencing to detect potential off-target mutation. No off-target mutation was detected.
(b) Potential off-target sites in the genome predicted by COSMID and CRISPROR were subjected to Sanger
Sequencing and no mutations were detected.
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(c) Sections of the cerebral cortex from control and C99F knock-in mice at postnatal day 0 (P0) were subjected to
immunohistochemistry using PHF6 antibody and the DNA dye bisbenzimide (Hoechst). PHF6 expression was
reduced in the cortical plate in C99F mice. Scale bar = 50um.
(d) Body weight of PHF6 C99F mice (n = 12) was slightly reduced compared to control littermate mice (n = 12).
Data are presented as mean ± SEM. Two-way repeated measure ANOVA, *p<0.05.
(e-f) PHF6 C99F knock-in mice has slightly reduced body length (e) and body surface (f) compared to control.
(g-i) No differences in BMI (g), ear length (h), facial length and interocular distance (i) between C99F and control.
(j-k) No differences in normalized testicular weight between C99F and control.
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Figure S2
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Figure S2. Behavior phenotyping of PHF6 C99F knock-in mice.
(a) Control (n = 12) and PHF6 C99F knock-in mice (n = 12) were tested on the conditioned fear procedure. (Left
panel): Freezing levels were not found to be different during either the 2-min baseline period or during tone-shock
(CS-US) training on day 1. (Right panel): Freezing levels were also observed to be similar during the 2-min altered
context baseline on day 3, although the C99F knock-in mice displayed reduced freezing response compared to
controls during the auditory cue test.
(b) No performance differences were observed between the C99F knock-in (n = 12) and control (n = 12) groups for
the cued or place (spatial learning) trials in the Morris water maze.
Two way repeated measure ANOVA, followed by pair-wise comparisons that were Bonferroni adjusted. *p <0.05.
Data are presented as mean ± SEM.
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Figure S3
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Figure S3. Additional cohort of C99F knock-in mice show deficits in cognition, social interaction and
emotionality.
(a) (Left panel) Testing the control (n = 11) and PHF6 C99F knock-in mice (n = 11) on the conditioned fear
procedure revealed that the two groups displayed similar freezing levels during the 2-min baseline and tone-shock
training periods on day 1. (Middle panel) The C99F knock-in mice exhibited reduced freezing levels during the
contextual fear test (genotype x minutes interaction: F(7,140) = 4.34, p = 0.014), particularly during the first two
minutes of the test session. (Right panel) Although the C99F knock-in mice generally displayed lower freezing
levels compared to controls, no significant overall effects involving genotypes were found for the auditory cue data.
(b) The percentage of time control mice, but not PHF6 C99F knock-in mice from the first cohort, interacted with the
novel mice was significantly above chance (**p<0.01, one sample t-test).
(c) Control mice (n = 13), but not C99F knock-in mice (n = 12) from the second cohort displayed a increasing trend
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in time spent for investigating a novel mouse than a cagemate.
(d) The percentage of time control mice, but not PHF6 C99F knock-in mice from the second cohort, interacted with
the novel mice was significantly above chance (**p<0.01, one sample t-test).
(e) PHF6 C99F knock-in mice (n = 12) displayed reduced ambulatory activities compared to control (n = 13) in the
open field test.
(f) PHF6 C99F knock-in mice (n = 12) displayed reduced rearing frequency compared to control (n = 13) in the
open field test.
(g) C99F knock-in mice (n = 12) displayed reduced acoustic startle response compared to control littermate animals
(n = 13).
*p<0.05, ***p<0.001, ****p<0.0001, unless specified, two-way repeated measures ANOVA, followed by pair-wise
comparisons that were Bonferroni adjusted were used for statistical analysis. Data are presented as mean ± SEM.
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Figure S3.
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Figure S4. Altered intrinsic membrane properties and AP threshold in two subpopulations
of stellate cells in C99F mice.
Stellate cells in KI mice were subdivided in two size groups according to cell capacitance (small
size and large size groups).
(A-E) Altered intrinsic membrane properties cannot be attributed to changes in cell size in KI
mice. No detectable changes in RMP were observed in either subgroup (A). Increased input
resistance (C,D) and decreased AP threshold (E) were observed in both groups in KI mice,
although a significant decrease in membrane capacitance was observed only in small size group
(B). ns, not significant, ** P<0.01 for KI vs WT; ## P<0.01 for small vs large C99F groups.
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Material and Methods
Plasmids
PHF6 patient mutations del 279-365, R342X, H229R, C45Y, C99F, C305X and R257G
were generated using site-directed mutagenesis and subcloned into the pHAGE-NTAP vector.

Animals
Rodents were maintained under pathogen-free conditions. All animal experiments were
done according to protocols approved by the Animal Committee of Washington University
School of Medicine and in accordance with the National Institutes of Health guidelines.
Target specific sgRNAs (5’-GTGATGTGAAAACCTGCCAC-3’) were cloned into BbsI
digested plasmid pX330 (addgene # 42230) and sgRNA cleavage activity was validated in vitro
by transfecting NIH3T3 cells, followed by T7E1 assay (NEB). T7 sgRNA and Cas9 templates
for in vitro transcription were pcr amplified, gel purified, and in vitro transcribed with the
MEGAshortscript T7 kit (sgRNA, Life Technologies) or the T7 mMessage mMachine Ultra kit
(Cas9, Life technologies). After transcription, both RNAs were purified with the Megaclear kit
(Life Technologies). A 200nt ssODN donor DNA with the mutation(s) centered within the oligo
was synthesized by IDT as an ultramer oligo. Injection concentrations were: 50ng/ul Cas9,
25ng/ul gRNA, 100ng/ul ssODN. All animal experiments were approved by institutional IACUC
protocols. B6/CBA F1 mice at 3-4 weeks of age (JAX Laboratories, Bar Harbor ME, USA) were
superovulated by intraperitoneal injection of 5 IU pregnant mare serum gonadotropin, followed
48h later by intraperitoneal injection of 5 IU human chorionic gonadotropin (PMS from SIGMA,
HGC from Millipore USA). Mouse zygotes were obtained by mating B6/CBA stud males with
superovulated B6/CBA females at a 1:1 ratio. One-cell fertilized embryos were injected into the
pronucleus and cytoplasm of each zygote. Microinjections and mouse transgenesis experiments
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were performed as described previously (Behringer et al., 2014). Our founder animals that were
mosaic for the nt.296G > T (p.C99F) missense mutation and nt. 298insG frameshift mutation
using a pyrosequencing. Two mutation alleles were segregated in F1 generation, and their
genotypes were confirmed with Sanger sequencing. Based on detailed molecular
characterization, we confirmed nt. 298insG line is a null.

Antibodies
Antibodies include PHF6 (Novus biological, NB100-68262), Ctip2 (Abcam ab18465), 14-3-3β
(Santa Cruz, sc-1657), Flag (Sigma f7425).

Immunohistochemistry
The brain from mice at distinct ages were fixed with 2% PFA and 4% sucrose and
subjected to cryosectioning. Sections were blocked with blocking buffer (10% goat serum, 3%
BSA, and 0.4% Triton-X in PBS), and subjected to immunofluorescence analyses with rabbit
anti-PHF6 and/or rat anti-CTIP2. The DNA dye bisbenzimide (Hoechst 33258) was used to label
cell nuclei. Confocal images were acquired with Olympus FV1200 with identical scanning
configurations for all samples in the same experiment.

One-hour locomotor activity and open-field behavior test
Mice in cohorts 1 and 2 were evaluated over a 1-h period in transparent enclosures as previously
described (Dougherty et al., 2013). Each cage was surrounded by a frame containing a 7 × 15
matrix of photocell pairs, the output of which was fed to an on-line computer (Kinder Scientific,
LLC, Poway, CA). The system software was used to define a 33 × 11 cm central zone and a
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peripheral or surrounding zone that was 5.5 cm wide with the sides of the cage being the
outermost boundary. In cohort 3, ambulatory activity and exploratory behaviors of the C99F and
control mice were quantified (Wozniak et al., 2013) over a 1-h period in an open-field
(41×41×38.5 cm high) constructed of Plexiglas, which utilized computerized photobeam
instrumentation that included a frame containing a 16×16 matrix of photocell pairs surrounding
the apparatus. Total ambulations (whole body movements) and vertical rearing frequency were
computed using system software (Kinder Scientific, LLC) and were analyzed for both tests.
Conditioned fear
Mice were trained and tested using two clear-plastic conditioning chambers (26×18×18 cm high)
(Med-Associates, St. Albans, VT) easily distinguished by different olfactory, visual, and tactile
cues present in each chamber as described (Wozniak et al., 2007). On day 1, each mouse was
placed into the conditioning chamber for 5 min and freezing behavior was quantified using
FreezeFrame image analysis software during a 2 min baseline period. After baseline
measurements, a conditioned stimulus (CS) consisting of an 80 dB tone (white noise) was
presented for 20 seconds followed by an unconditioned stimulus (US) consisting of a 1 s, 1.0 mA
continuous foot shock. This tone-shock (T/S) pairing was repeated each minute over the next 2
min, and freezing was quantified after each of the three tone-shock pairings. Twenty-four hours
after training, each mouse was placed back into the original conditioning chamber to test for fear
conditioning to the contextual cues in the chamber. Twenty-four hours later, each mouse was
placed into the other chamber containing distinct cues. Freezing was quantified during a 2
minutes “altered context” baseline period as well as over a subsequent 8 min period
during which the auditory cue (CS) was presented. Shock sensitivity was evaluated
following completion of the conditioned fear test, which involved determining shock levels that
elicited flinching, escape-related behaviors and vocalization.
Novel object and novel location recognition
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Using a previously published protocol (Brown et al., 2010), each mouse was habituated to the
test chamber over two days and on the following day given two sample trials and two test trials.
For novel object recognition, a sample trial consisted of placing a mouse in the familiar arena
that contained two copies of the same object and allowing it to explore for 10 min, and then
returning it to its home cage. A 10-min test trial was conducted following a 50-min delay, when
a mouse was placed back into the test arena, where a novel object was presented along with the
copy of the familiar object used during the sample trial. Fifty minutes later, another 10-min
sample trial was administered in which two new novel objects were placed in opposite corners of
the arena. Mice were again returned to their home cage for a 50 min delay, then placed back into
the test arena where one of the objects had been moved to a novel location. The amount of time
each animal spent actively investigating the objects was manually scored and the investigation
times for the novel versus the familiar object (or locations) were analyzed as a measure of
recognition memory.
Social Approach
Sociability and preference for novel social interactions were evaluated in a rectangular apparatus
divided into three chambers each measuring 19.5cm x 39cm x 22 cm according to previously
published methods (Dougherty et al., 2013). Two small stainless steel withholding cages (Galaxy
Pencil/Utility Cup, Spectrum Diversified Designs, Streetsboro, OH) were used to prevent contact
between test and stimulus mice with one being placed in each outer chamber. Test sessions were
recorded using a digital camera connected to a PC and scored using the ANY-maze (Stoelting,
Co, Wood Dale, IL) software program. Time spent, distance traveled, entries into, and latency to
enter each chamber and the investigation zones around the holding cages were analyzed. Each
test session contained five consecutive, 10-min trials, with the first two trials being dedicated to
habituation to the apparatus without stimulus animals present followed by three test trials. After
habituation, sociability exhibited toward a novel stimulus mouse versus a familiar, empty
withholding cage was assessed in the first test trial by placing an unfamiliar, gender-matched
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stimulus mouse in one withholding cage while the other was left empty, and the test mouse was
allowed to freely explore the apparatus and investigate the novel mouse in the withholding cage.
For the second test trial, a gender-matched cagemate was placed in one withholding cage while
the other remained empty, and the test mouse could freely explore the apparatus and investigate
the cagemate in the withholding cage. During the third test trial, the familiar cagemate remained
in the withholding cage, although a new, unfamiliar gender-matched stimulus mouse was now
placed in the other withholding cage, and the test mouse was allowed to explore the apparatus
and investigate the two mice contained in the withholding cages. Entries, latency to enter, and
time spent in each chamber and investigation zone were recorded for each mouse.
Acoustic startle response/prepulse inhibition
Sensorimotor reactivity and gating were evaluated in the mice by quantifying the magnitude of
their acoustic startle (ASR) and PPI responses (Hamilton Kinder, LLC) as previously described
(Yuede et al., 2010). In the first cohort, a startle response to a 120 dB auditory stimulus pulse (40
ms broadband burst) and PPI (response to a prepulse plus the startle pulse) were measured
concurrently in mice. Beginning at stimulus onset, 1 ms force readings were averaged to obtain
an animal's startle amplitude. A total of 20 startle trials were presented over a 20 min test period
during which the first 5 min served as an acclimation period when no stimuli above the 70 dB
white noise background were presented. The session began and ended by presenting 5
consecutive startle (120 db pulse alone) trials unaccompanied by other trial types. The middle 10
startle trials were interspersed with PPI trials (consisting of an additional 30 presentations of 120
dB startle stimuli preceded by pre-pulse stimuli of either 4, 12, or 20 dB above background (10
trials for each PPI trial type). A percent PPI score for each trial was calculated using the
following equation: %PPI = 100*(ASRstartle pulse alone - ASRprepulse+startle
pulse)/ASRstartle pulse alone Another cohort was tested using an upgraded instrumentation
system (Kinder Scientific, LLC), and a slightly modified protocol. This involved evaluating
startle responses to increasing sound pressure levels (80 to 110 dB), as well as the startle
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response to 120 dB collected over 20 trials as described above. Pre-pulse levels tested in this
cohort were 4, 8, and 16 dB above background, and PPI was calculated using the same equation.
Morris Water Maze Test
Reference memory was evaluated in the mice using the Morris Water Maze navigation test
similar to previously published procedures (Wozniak et al., 2004). The protocol included cued
(visible platform), place (submerged, not visible platform), and probe trials (platform
removed). Testing took place in a round pool (118 cm diameter) containing water made
opaque with non-toxic white tempura paint. All trials were monitored through a live video
feed by computer software (Any-maze, Stoelting Co., Wood Dale, IL) which calculated swim
speed, escape path length, escape latency, and time and distance spent in each of the four
quadrants of the pool. The maximum score for all water maze trials was 60 s. Cued trials were
conducted first to determine if nonassociative deficits (e.g., visual or sensorimotor
disturbances, or alterations in motivation) were likely to affect swimming performance and
confound interpretation of the acquisition data collected during the place trials. Mice received
4 cued trials per day for 2 consecutive days. Mice were placed in the quadrant directly
opposite a submerged platform marked with a visible cue. The platform was moved to a
different location for each trial within a day and there were very few distal cues available
during this time, both of which limited spatial learning. Escape path length and latency and
swimming speeds were used to evaluate performance during the cued and place conditions.
Place trials were performed following the cued trials. Stationary distal cues to facilitate
learning were placed around the room and mice were evaluated on their ability to learn the
location of a hidden, unmarked platform. Four place trials per day were administered for 5
consecutive days during which the platform remained in the same location for all trials. The
mice were released from 4 different locations each day. The daily protocol involved
administering 2 sets of 2 trials each, with sets being separated by approximately 1 hr. A single
probe trial was administered approximately 1 hr after completion of place trials on the fifth
56

day. During the probe trial, the platform was removed from the pool and the animals placed in
the quadrant directly opposite the former platform location. Mice were allowed to explore for
60 s during which time various aspects of their search behaviors for the platform were
quantified. The number of times a mouse passed directly over the platform location (platform
crossings), the time spent in the target quadrant that had contained the platform, and spatial
bias (preference for the target quadrant compared to other quadrants) were used to evaluate
retention performance during the probe trial.

Seizure induction
Pentylenetetrazole (Sigma) dissolved in 0.9% saline was injected intraperitoneally
(75mg/kg) into 5-7 month old mice as described (Zhang and Wong, 2012). Mice then were
placed individually into cages for observation. A trained blinded observer performed the
experiment. Generalized seizure was characterized by sudden loss of upright posture with diffuse
tonic posturing followed by clonic shaking. The time to the generalized seizure was recorded for
each mouse.
Kainic acid (Sigma) dissolved in the 0.9% saline was injected intraperitoneally
(25mg/kg) into 5-7 month old mice. Mice then were placed individually in cages for observation
and only two mice were simultaneously observed. Mouse genotypes were blinded from the
experimenter. The Racine scale was used to score seizure progression in mice as described
(Racine, 1972). A score of 1 was assigned when mice displayed absence-like immobility and
oro-alimentary movements. Mice received a score of 2 for hunching with facial or manual
automatisms and head bobbing. Mice scored 3 rearing with facial or manual automatisms and
forelimb clonus, and achieved a score of 4 with repeated rearing with continuous forelimb clonus
and falling. Score of 5 was assigned if mice displayed generalized tonic-clonic seizure with
lateral recumbence or jumping. Death was also scored as 5. Mice were scored every five-minute
for 100 minutes.
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Electrophysiology
Animals and slice preparation
Electrophysiological recordings were conducted blind to genotype. Slices were prepared
as described (Deng and Klyachko, 2016). In brief, 18-23-day-old male mice were used. After
deep anesthesia with CO2, mice were decapitated and the brain was dissected out in ice-cold
saline containing (in mM): 130 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 5.0
MgCl2, and 10 glucose, pH 7.4 (saturated with 95% O2 and 5% CO2). Horizontal brain slices
(350 µm) including the entorhinal cortices were cut using a vibrating microtome (Leica
VT1100S). Slices were initially incubated in the above solution at 35°C for 1 h for recovery and
then kept at room temperature (~23°C) until use. All animal procedures were in compliance with
the US National Institutes of Health Guide for the Care and Use of Laboratory Animals, and
conformed to Washington University Animal Studies Committee guidelines.

Action potential recording and threshold determination
Whole-cell patch-clamp recordings using a Multiclamp 700B amplifier (Molecular
Devices) in current-clamp mode were made from stellate cells of EC superficial layers visually
identified with differential interference contrast optics (Olympus BX51WI). Current-clamp
recordings were made with pipette capacitance compensation and bridge-balance compensation.
Stellate cells were identified according to morphology and electrophysiological properties as
described (Deng et al., 2007). All recordings were conducted at near-physiological temperature
(33–34°C). The recording electrodes were filled with (in mM): 130 K-gluconate, 10 KCl, 0.1
EGTA, 2 MgCl2, 2 ATPNa2, 0.4 GTPNa, and 10 HEPES, pH 7.3. The extracellular solution
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contained (in mM): 125 NaCl, 24 NaHCO3, 3.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, and 10
glucose, pH 7.4 (saturated with 95% O2 and 5% CO2).
For neuronal excitability measurements, cell membrane potential was set to given
potentials (-55 to -44 mV with 1-mV step) through automatic current injection. Action potential
(AP) firing probability and the number of APs within 20s was averaged from 4-5 trials for each
cell. For AP threshold determination, APs were evoked by a ramp current injection (0.15 pA/ms)
(Deng and Klyachko, 2016; Yamada-Hanff and Bean, 2013) with a hyperpolarizing onset to
ensure maximal Na+ channel availability before the 1st AP. The threshold was defined as the
voltage at the voltage trace turning point, corresponding to the first peak of 3rd order derivative
of AP trace (Deng and Klyachko, 2016). Ramp current-evoked AP threshold was then defined as
the mean threshold of the first AP in the train averaged over 5-8 trials.
Determination of resting membrane potential, capacitance and input resistance
Resting membrane potential (RMP) was measured immediately after whole-cell
formation. Cell capacitance was determined by the amplifier’s auto whole-cell compensation
function with slight manual adjustment to optimize the measurement if needed. The obtained
values then were used for input resistance normalization. In current-clamp mode, a negative
current (−50 pA for 500 ms) was injected every 5 s to assess the input resistance.
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ABSTRACT
PHF6 is a plant homeodomain finger protein implicated in X-linked intellectual disability
disorder Börjeson-Forssman-Lehmann syndrome (BFLS). PHF6 is located in the nucleus and
might regulate transcription. How PHF6 functions in the nucleus and its relevance to BFLS
remains unclear. We generated PHF6 knockout and C99F knock-in mice using CRISPR-Cas9
technology. We discovered the molecular function of PHF6 in regulating gene expression in the
developing cortex. Transcriptomic analysis of the cerebral cortex in C99F knock-in mice and
PHF6 knockout mice show that PHF6 promotes the expression of neurogenic genes and
concomitantly suppresses the expression of synaptic genes, suggesting that PHF6 may maintain
neurons in an immature state and knockout of PHF6 leads to precocious differentiation.
Interestingly, PHF6-regulated genes are overrepresented in gene signatures and modules that are
deregulated in the brain of patients with autism spectrum disorders. Our findings advance our
understanding of the mechanisms underlying BFLS pathogenesis and may suggest a potential
link between BFLS and autism spectrum disorders.
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INTRODUCTION
PHF6, in plant homeodomin zinc finger protein (PHD) family, is a 365 amino acid
protein that contains two PHD-like zinc fingers and nuclear and nucleoli localization sequences.
PHD-like zinc fingers are often found in components of chromatin remodeling proteins as
epigenetic readers that interact with modified histones. Therefore, PHF6 is often regarded as a
transcriptional regulator.
Mutations in PHF6 have been implicated in syndromic form of X-linked intellectual
disability, Börjeson-Forssman-Lehmann syndrome (BFLS). Most of the mutations identified in
BFLS patients are missense mutation leading to single amino acid change (Lower et al., 2002,
Gecz et al., 2006). These mutations are distributed across the PHF6 gene. Some mutations in
PHF6 lead to decreased protein level, suggesting that BFLS may result from hypomorphic PHF6
function. How do these mutations regulate gene expression compared to a null allele, and what is
the residual function of the mutant allele has yet to be discussed.
PHF6 protein is localized in the nucleus and interacts with the PAF1 transcription
elongation factor complex, NuRD chromatin remodeling complex, and upstream binding factor
UBF1 (Liu et al., 2014b; Todd et al., 2015; Zhang et al., 2013). In the leukemia biology, PHF6
regulates chromatin accessibility to lineage-specific transcription factors. PHF6 promotes genes
involved in B-cell development and represses genes involved in T-cell signaling. And loss of
PHF6 leads to a lymphoma with mixed-lineage in vivo (Feliciano et al., 2017)
. In the nervous system, knockdown of PHF6 in the mouse cerebral cortex impairs the migration
of cortical neurons, leading to white matter heterotopias (Zhang et al., 2013), suggesting a role
for PHF6 in the regulation of cortical neuron positioning. Accordingly, PHF6 is thought to
regulate transcription in neurons (Zhang et al., 2013). How PHF6 regulation of gene expression,
particularly at a genome-wide level, impacts BFLS pathogenesis remains incompletely
understood.
In this study, we report the first patient-specific PHF6 mutant mouse model of BFLS and
a whole body knockout mouse of PHF6. Genome-wide RNA-seq analyses of the cerebral cortex
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in PHF6 C99F and PHF6 knockout mice show that PHF6 promotes the expression of neurogenic
genes and concomitantly suppresses the expression of synaptic genes. PHF6-regulated genes are
overrepresented in autism spectrum disorder (ASD) relevant gene signatures including gene
modules that are misregulated in the brain of ASD patients. Consistently, we have identified an
ASD patient with an underlying PHF6 missense mutation. Collectively, our findings broaden our
understanding of the cellular and molecular underpinnings of BFLS pathogenesis, and may
suggest a potential link between BFLS and ASD.

64

RESULST
PHF6 regulates neurogenic and synaptic genes during brain development
Having identified PHF6 C99F knock-in mice as a novel model of BFLS, we next
characterized the mechanism by which PHF6 deficiency might contribute to BFLS pathogenesis.
Due to PHF6’s putative transcriptional role, we subjected the cerebral cortex from P0 PHF6
C99F mice and control littermate to RNA-seq analyses. Surprisingly, the expression of only 48
genes was altered in PHF6 C99F mice with false discovery rate (FDR)<0.05 in EdgeR analyses.
Because the C99F mutation leads to substantial but incomplete downregulation of PHF6 protein
(Figure 1e), the presence of residual PHF6 protein in these mice might not allow detection of
robust transcriptional changes. Fortuitously, in the process of generating the C99F allele, a
nucleotide insertion adjacent to the Cas9 cleavage site was also obtained, leading to a frameshift
mutation and consequent knockout of PHF6 in mice (Figure S5a-b). Unlike the C99F knock-in
mice, PHF6 knockout (KO) animals died perinatally. Consisent with the prediction that PHF6
KO mice might provide a more robust means for identification of PHF6-regulated genes, the
expression of 193 genes was significantly altered (FDR<0.05 in EdgeR) in the cerebral cortex of
PHF6 KO mice compared to control littermate animals (Figure 6a). Transcriptomic analysis
using DEseq2 showed that 87.5% differentially expressed genes upon PHF6 KO overlapped with
those obtained by EdgeR analyses (Figure S5d-e). Notably, alterations in gene expression in the
cerebral cortex upon PHF6 KO with FDR<0.05 correlated significantly with changes in their
expression in PHF6 C99F mice (Figure 6b), supporting the interpretation that the C99F mutation
may act as hypomorphic allele in the regulation of gene expression. In control permutation
analyses, the observed r=0.48 was highly significant compared to 10,000 random samplings of
193 gene pairs in PHF6 KO and C99F mice (p = 8.5e-8) (Figure 6c). Additionally, significantly
downregulated and upregulated genes upon PHF6 KO (FDR<0.05) were also downregulated and
upregulated, respectively, in PHF6 C99F mice (Figure 6d). We therefore focused subsequent
analyses on deregulated genes in the cerebral cortex of PHF6 KO mice.
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Using the dataset that contains genes enriched in major brain cell types (Zeisel et al.,
2015), we found that PHF6-regulated genes were enriched in interneurons and excitatory
neurons (Figure 6e) but not in glia cells, suggesting that PHF6-regulated genes are represented in
neurons. In DAVID gene ontology (GO) analyses, genes encoding potassium transport, terminal
bouton, and synapse proteins were found among upregulated genes, whereas genes encoding
developmental, zinc finger, and cell differentiation proteins were found among downregulated
genes in the cerebral cortex of PHF6 KO mice (Figure 6f). These analyses suggest that PHF6
promotes the expression of differentiation genes and concomitantly suppresses the expression of
synaptic genes in the cerebral cortex.
We next characterized the developmental expression pattern of PHF6-regulated genes in
the human brain, using the available developing human brain transcriptome dataset-BrainSpan
(BrainSpan, 2013). PHF6 mRNA was significantly downregulated beginning at post-conceptual
week 8 (pcw8) during human brain development in the ventral frontal cortex (VFC) (Figure S5c),
mimicking its expression pattern in mice. In contrast, doublecortin (DCX) was upregulated from
pcw8 to pcw24 and subequently downregulated (Figure S5c). Importantly, the expression of
genes upregulated upon PHF6 loss steadily increased throughout human development from pcw8
to 40 years of age in the VFC, similar to the expression pattern of genes for chemical synaptic
transmission (Figures 6g-i). Concomitantly, genes downregulated upon PHF6 loss had high level
of expression at early time points during human brain development but steadily declined starting
at pcw8, displaying a similar pattern as genes encoding neurogenesis (Figures 6g-i). Similar
results were observed in other brain regions including the dorsal frontal cortex (DFC), medial
frontal cortex (MFC), and primary somatosensory cortex (S1C) (Figure S5d). Similar
developmental expression patterns were observed for upregulated and downregulated genes upon
PHF6 loss identified using DEseq2 analyses (Figure S5d-e). Together, our data suggest that
PHF6 maintains neurons in an immature state and that PHF6 loss may lead to premature
downregulation of neurogenic genes and activation of synaptic genes (Figure 7).
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Transcriptomic comparisons between PHF6 knockout and C99F knock-in mice
Having established that genes altered in PHF6 KO and C99F mice were mildly correlated,
we further characterized the relationship between PHF6 KO and C99F based on gene expression.
We reasoned that the commonly regulated genes in both PHF6 KO and C99F might represent the
genes involved in the disease pathogenesis, whereas the uncorrelated genes between PHF6 KO
and C99F were genes that are deregulated specifically in PHF6 knockout. We therefore separated
the 193 genes misregulated genes into two groups using arbitrary log fold change cut off of Log2
= 0.2. From the genes that were significantly changed upon PHF6 knockout, we focused on the
genes that were also altered by at least 1.15 fold in PHF6 C99F with the same direction of
change. With this cut off, genes could be divided into two groups, KO-KI common genes,
containing genes that were highly correlated between PHF6 KO and C99F (r = 0.72); and KOspecific genes with genes uncorrelated between PHF6 KO and C99F (r = 0.22) (Figure 8a-b). In
the KO-KI common gene group, the downregulated genes upon PHF6 KO were dramatically
downregulated in PHF6 C99F, and the upregulated genes upon PHF6 KO were largely
upregulated in PHF6 C99F (Figure 8b, d). In addition, KO-specific genes represent a large
proportion of genes deregulated upon PHF6 loss compared to KO-KI common genes (Figure 8c),
suggesting that the majority of the genes deregulated upon PHF6 knockout were not represented
in PHF6 C99F mice.
To further characterize the biological function of the KO-specific and KO-KI common
genes, we performed gene ontology analysis. Interestingly, KO-specific genes shared almost the
same terminologies with all deregulated genes upon PHF6 knockout (Figure 9a). We asked
whether precocious differentiation phenotype discovered from 193 deregulated genes (in PHF6
KO) were also represented by KO-specific genes. The downregulated and upregulated KOspecific genes were therefore analyzed across human developing brains using Brainspan dataset.
Strikingly, similar developmental pattern was found using KO-specific genes as with 193
misregulsted genes (Figure 6h, 9c). In contrast, KO-KI common genes shared terminologies
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including cell spreading, signaling and cilia (Figure 9b). These genes did not recapitulate the
developmental pattern observed from KO-specific genes (Figure 9c). These data suggest that
precocious differentiation identified from 193 deregulated genes upon PHF6 knockout could be
the characterized by the KO-specific genes alone, and thus a potential KO-specific phenotype.
However, KO-KI commonly regulated genes were not involved in maturation. To strength this
observation, we loosened the FDR threshold of the differentially expressed genes in PHF6 C99F
by FDR<0.2, the average gene expression was also not altered (data not shown). Taken together,
these data suggest that PHF6 C99F harbor hypomorphic function of PHF6. Consistent with this
finding, the density of dendritic spines in layer II stellate neurons in the entorhinal cortex did not
appear to increase prematurely in PHF6 C99F mice (Figure S5i-j). These data again strengthen
the hypothesis that PHF6 C99F may not lead to precocious differentiation of neurons.

PHF6-regulated genes are implicated in neurodevelopmental disorder of cognition
Because PHF6 mutations cause ID, we reasoned that differentially expressed genes in
PHF6-deficient cortex might be also regulated by proteins implicated in other
neurodevelopmental disorders of cognition. We therefore compared PHF6-regulated genes with
targets of FMRP, which is the most common single gene cause of ID (Coffee et al., 2009; Pieretti
et al., 1991). Upregulated genes upon PHF6 loss overlapped significantly with FMRP targets
(Darnell et al., 2011) (Figure 6j), suggesting that PHF6 and FMRP regulate a common group of
genes. In other analyses, downregulated genes upon PHF6 loss overlapped significantly with
differentially expressed genes in the cerebral cortex of mice in which the histone H3K4me3 and
H3K4me2 demethylase protein KDM5C was knocked out (Iwase et al., 2016) (Figure 6j), and
with misregulated genes in the cerebral cortex of mice with haploinsufficiency of the chromatin
remodeling protein CHD8 (Gompers et al., 2017) (Figure 6j). Together, these observations
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suggest that PHF6-regulated genes overlap with targets of other proteins associated with
developmental disorders of cognition.
Because PHF6-regulated genes overlap with targets of FMRP and CHD8, which are both
linked to autism in addition to ID (Bassell and Warren, 2008; Bernier et al., 2014; Iossifov et al.,
2012), we asked whether PHF6-regulated genes might also be relevant to autism spectrum
disorder (ASD). We intersected PHF6-regulated genes with the unbiased autism gene module
termed asdM12 that is misregulated in the frontal and temporal cortex in ASD patients
(Voineagu et al. 2011). Remarkably, upregulated genes upon PHF6 loss overlapped significantly
with the asdM12 gene module (Figure 6j), suggesting that PHF6 may regulate gene programs
that are implicated in ASD.
ASD genes converge on modules that regulate synaptogenesis during human cortical
development (Berg and Geschwind, 2012; Parikshak et al., 2013). We mapped PHF6-regulated
genes onto available developmental modules containing gene networks co-regulated across
developmental stages, generated by weighted gene coexpression network analysis (WGCNA)
using BrainSpan whole-genome transcriptomic data (Parikshak et al., 2013). Downregulated
genes upon PHF6 loss were over-represented in module 3 (M3), enriched for genes encoding
chromatin organization, and module 8 (M8), enriched for genes encoding neuron differentiation.
In addition, upregulated genes upon PHF6 loss were over-represented in module 13 (M13) and
module 17 (M17) (Figure 6k), enriched for synaptic genes. The GO terms and temporal
expression of over-represented gene modules were similar to misregulated genes upon PHF6 loss
(Figure 6f, S5e, f). Strikingly, upregulated genes upon PHF6 loss and the autism-associated
asdM12 gene module converged onto the developmental modules M13 and M17 representing
synaptic terms (Figure 6k, S5e,f). These results suggest that PHF6-regulated genes and the
autism-linked gene modules coalesce in developmental modules.

Mutation of PHF6 in a patient with BFLS and autism spectrum disorder
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The identification of a link between PHF6-regulated gene expression in the mouse
cerebral cortex and human brain gene networks deregulated in autism raised the question of
whether BFLS patients might present with autism spectrum disorder (ASD). Reports of the
clinical presentation of BFLS do not include ASD symptomatology (Jahani-asl et al., 2016).
However, in a recent series of patients with neurodevelopmental disorders undergoing exome
sequencing, we identified a patient with ASD harboring a pathogenic nonsense mutation of
PHF6 at Cysteine 305 (Baldridge et al., 2017). The purpose of the series was to assess the role of
the clinician in the interpretation of exome sequencing results toward diagnosis of genetic
disorders (Baldridge et al., 2017). The PHF6 C305X mutation was mentioned in a table, and a
few patient symptoms were briefly listed in supplementary material (Baldridge et al., 2017).
Here, a summary of the case is presented. A now 20-year-old woman was born as a full-term
infant with normal weight and length. Soon after birth, parents reported difficulties in feeding
coordination. She did not babble as an infant, did not speak words until 4 years of age, and began
to speak in sentences at age 6. At two years, she continued to show significant language delay,
with no speech, but could sign 3-4 words and follow commands. The patient was diagnosed with
pervasive developmental disorder at age four. Later, in addition to cognitive impairment, the
patient displayed aggressive behavior. She also developed repetitive behaviors and deficits in
social interaction. These clinical features, combined with clinical observation and parental and
teacher evaluations on the Social Responsiveness Scale (SRS), led to diagnosis of autism
spectrum disorder (ASD) at age 11. Clinical exome sequencing at age 17 revealed a de novo
mutation (c.915_916delTGinsAA, p.C305X, NM_032458) in the PHF6 gene (Baldridge et al.,
2017). X-inactivation testing showed an X-inactivation ratio of 100:0, consistent with a highly
skewed X-inactivation. The C305X mutation was not present in the Exome Aggregation
Consortium (ExAC) or Genome Aggregation Database (gnomeAD) database (data not shown),
suggesting that the C305X mutation is pathogenic. The C305 mutation is located in the alpha
helix of the second PHD domain of PHF6, which like C99F is an evolutionarily conserved zincchelating cysteine (Liu et al., 2014). Like the C99F mutation, the C305X mutation led to
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substantial downregulation of PHF6 protein level in cells (Figure S5g). Collectively, these data
suggest that loss of function mutations in PHF6 may cause BFLS with autism.
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DISCUSSION
In this study, we report the first mouse model of Börjeson-Forssman-Lehmann syndrome
(BFLS) and a mouse with knockout of PHF6. Gene profiling analyses in PHF6-deficient mice
show that PHF6 promotes the expression of neurogenesis genes and concomitantly suppresses
expression of synaptic genes. PHF6-regulated genes are overrepresented in gene signatures and
modules that are deregulated in the brain of patients with autism spectrum disorder (ASD).
Taken together, our findings provide novel insights into the cellular and molecular underpinnings
of BFLS, and may suggest potential links of BFLS with autism spectrum disorders.
Our study also provides novel insights on the role of PHF6 in brain development. The
findings that PHF6 promotes the expression of neurogenesis genes and downregulates synaptic
gene suggest that PHF6 may control the timing of neuronal differentiation, possibly preventing
premature connectivity. Thus, deregulation of temporal control of neuronal maturation may
contribute to the pathogenesis of neurodevelopmental disorders of cognition.
Analyses of PHF6-regulated genes also suggest molecular convergence with gene
signatures and modules of autism spectrums disorder (ASD). Notably, clinical descriptions of
BFLS are focused on intellectual disability and syndromic features of the disorder (reviewed in
Jahani-Asl et al., 2016). However, our analyses of PHF6-regulated genes suggest potential links
between BFLS and ASD. Consistent with this interpretation, we have identified a patient with
ASD harboring the pathogenic nonsense PHF6 mutation C305X (Baldridge et al., 2017). In
future clinical studies, it will be interesting to explore whether ASD features are present in other
BFLS patients.
In summary, we report a novel mouse model of BFLS that features cognitive impairment
and predisposition to seizures. Our findings also raise the possibility that autism may represent a
component of BFLS. Our study advances understanding of the cellular and molecular
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underpinnings of BFLS, and lays the foundation for potential treatments for neurodevelopmental
disorders of cognition.
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Figure 6. Transcriptional alterations in the cerebral cortex in PHF6 deficient mice.
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(a) Heatmap of 193 differentially expressed genes upon PHF6 KO by RNAseq (EdgeR,
FDR<0.05)
(b) Correlation analysis of alteration of gene expression in the cerebral cortex of PHF6 C99F
mice that were deregulated upon PHF6 KO (193 genes; FDR<0.05).
(c) Spearman correlation rho distribution by comparing gene expression change in PHF6 KO and
C99F mice calculated by random sampling of 193 genes for 10,000 times. Red line: rho=0.48
(see b). Z score statistics, p=8.7e-8.
(d) Boxplot of log fold change of up and down-regulated genes upon PHF6 KO in C99F.
Wilcoxon rank-sum test, p=5.8e-4(upregulated), p=2.04e-5(downregulated).
(e) Gene enrichment analysis of major brain cell types. Dotted red line: p-adjusted=0.05.
(f) Gene ontology analysis by DAVID for downregulated and upregulated genes upon PHF6 KO.
(g) Average expression for neurogenic (GO:0050769) and synaptic (GO:0007268) genes across
developmental time in VFC based on BrainSpan dataset.
(h) Average expression of downregulated and upregulated genes upon PHF6 KO across
developmental time in the VFC based on BrainSpan dataset.
(i) Example of individual gene expression across development time.
(j) Enrichment analysis of up- and down-regulated genes upon PHF6 KO with gene targets of
FMRP, KDM5C, CHD8 and the autism module asdM12, containing misregulated genes in the
frontal and tempora l cerebral cortex in postmortem ASD patient brains.
(k) Enrichment analysis of misregulated genes upon PHF6 KO and the asdM12 gene module
with previously described developmental gene coexpression network modules.
Enrichment analysis was tested by hypergeometric-test, followed by Benjamini-Hochberg
multiple testing corrections. *p.adjusted <0.05, **p.adjusted <0.01, ***p.adjusted <0.001.
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Figure 7. Working model of PHF6 maintaining neurons in an immature state.
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Figure 8. Bioinformatic dissection of KO-specific and KO-KI commonly regulated genes.
(a) Using Log2 Fold change of 0.2, the 193 deregulated genes upon PHF6 knockout were
classified into two groups, KO-specific genes in green shade and KO-KI common genes in blue
shade.
(b) (Left) Comparison between KO and C99F transcriptome for KO-specific genes showed a low
correlation, Spearman, r=0.22. （Right) Comparison between KO and C99F for KO-KI
commonly regulated genes showed a high correlation, Spearman, r=0.72.
(c) The percentage of KO-specific genes (green) and KO-KI common genes (blue).
(d) Heatmaps of KO-KI common genes.
(e) Boxplot of log fold change of up and down-regulated genes upon PHF6 KO and C99F for
KO-specific and KO-KI common genes.
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Figure 9. Functional characterization of deregulated genes upon PHF6 knockout.
(a) Gene ontology of KO-specific genes.
(b) Gene ontology of KO-KI common genes.
(c) Average expression of downregulated and upregulated genes for KO-specific group (left) and
KO-KI common group (right) across developmental time in the ventral frontal cortex (VFC)
based on BrainSpan dataset.
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Figure S5. Gene expression in the PHF6 knockout mouse.
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(a) The level of PHF6 mRNA in the cerebral cortex of PHF6 knockout mice in RNA-seq analysis
(n = 4) was reduced compared to control mice (n = 4). Data are presented as mean ± SEM.
(b) Lysates of the cerebral cortex at P0 from control male and PHF6 knockout male mice were
subjected to immunoblotting with the PHF6 and 14-3-3β antibodies. Levels of PHF6 protein
were diminished in the cortex of PHF6 knockout mice.
(c) Expression of PHF6 (left) and DCX (right) during development in ventral frontal cortex
(VFC) using BrainSpan dataset. PHF6 was developmentally downregulated, and DCX was
transiently expressed from post conceptual week 8 (pcw8) to pcw24.
(d) Average expression of downregulated and upregulated genes upon PHF6 knockout
discovered by DEseq2 was plotted across developmental time in the VFC based on human
BrainSpan data. Downregulated genes upon PHF6 loss were also developmentally
downregulated, whereas upregulated genes upon PHF6 loss were developmentally upregulated.
(e) Enrichment analysis of misregulated genes upon PHF6 knockout discovered by DEseq2 and
the asdM12 gene module with previously described developmental gene coexpression network
modules (Parikshak et al., 2013). Upregulated genes upon PHF6 knockout coalesced with autism
gene modules. Enrichment analysis was tested by hypergeometric-test, followed by BenjaminiHochberg multiple testing corrections. **p.adjusted <0.01, ***p.adjusted <0.001.
(f) Average expression of up- and down-regulated genes upon PHF6 knockout in medial frontal
cortex (MFC), dorsal frontal cortex (DFC) and primary somatosensory cortex (S1C).
Downregulated genes upon PHF6 knockout were developmentally downregulated, and
upregulated genes upon PHF6 knockout were upregulated throughout development in these brain
regions.
(g) Average expression of genes in developmental modules M3, M8, M13 and M17 was plotted
across developmental time in the VFC based on human BrainSpan dataset.
(h) Genes from developmental modules including modules M3, M8, M13 and M17 were
subjected to gene ontology analysis using Metascape.
(i) Layer II stellate neurons in entorhinal cortex were subjected to biocytin injection. Spine
density from P7-9, P14-16 and P21-25 were analyzed. C99F neurons had little or no effect in
synaptogenesis. Scale bar = 2um.
(j) Quantification of spine density at P7-9, P14-16 and P21-25 from C99F and control stellate
neurons.
(k) Lysates of 293T cells transfected with the expression plasmids encoding FLAG-HA-tagged
PHF6, the control vector or patient specific PHF6 mutation C305X were subjected to
immunoblotting with the Flag and 14-3-3β antibodies, the latter serving as loading control.
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C305X led to reduced PHF6 protein level. Asterisk indicates non-specific immunoreactive band.
Arrowhead indicates FLAG-tagged PHF6.
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Material and Methods
RNA-seq
For control and PHF6 knockout (KO) experiment, four pairs of animals were harvested
from two litters. For control and PHF6 C99F knock-in experiment, five pairs were harvested
from three litters. Animals were harvested at postnatal day 0 (p0). The cerebral cortex was
dissected and subjected to RNA extraction using Trizol (Invitrogen). RNA from control/KO
experiment was sequenced on an Illumina HiSeq 2500, and RNA from control/C99F experiment
was sequenced on Illumina HiSeq 2500. EdgeR was used to analyze the differentially expressed
genes. The Benjamini-Hochberg false discovery rate (FDR) was calculated for all genes.

Permutation testing
Permutation testing was performed to assess the correlation between gene expression
alteration in the cerebral cortex of PHF6 knockout and C99F knock-in mice by comparing the
observed correlation value with expected correlation value. Observed valued was calculated by
Spearman correlation (rho) between log fold change (logFC) KO/control and C99F/control of
193 differentially expressed genes upon PHF6 KO, whereas the expected correlation distribution
was generated via iterative sampling of random sets of 193 genes and calculating the logFC
correlation between KO and C99F. Random sampling was repeated 10,000 times, allowing us to
estimate the mean and standard deviation of the expected rho distribution. Empirical z-scores and
p value were calculated for the observed rho value based on the expected rho distribution. A
custom R script was used for the analysis.

Gene enrichment analyses
For cell type enrichment, we used cell marker gene set previously described ((Zeisel et
al., 2015). We used the expressed genes in the postnatal day 0 (P0) mouse cortex averaging the
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RPKM (mean>0.1) across control samples, and overlapping with all the expressed genes in the
single cell RNA-seq dataset (Zeisel et al., 2015) as our background list.
For gene enrichment analysis with developmental modules and other ID proteins, all gene
symbols were converted into human orthologs using web based HUGO multi-symbol checker.
Expressed protein-coding genes in the P0 mouse cortex (RPKM > 0.1) were used as background
for KDM5C and CHD8 enrichment analysis. Protein-coding genes that had probes called in
Voineagu et al. 2013 were used as background for asdM12 enrichment analysis. For FMRP
enrichment analysis, all protein-coding genes detected in HITS-CLIP (Darnell et al., 2011) were
used as the background list, and FMRP enriched genes (765) were used as FMRP-target.
Expressed genes in the P0 mouse cortex (RPKM>0.1) that had human orthologs were used as
background for developmental module enrichment analysis.
All gene enrichment analyses were performed using one-sided hypergeometric test
calculated according to the R function phyper(). Each p-value was adjusted by BenjaminiHochberg correction.

BrainSpan developmental analyses
Normalized RPKM values of RNAseq data were obtained from Allen Brain Atlas
BrainSpan dataset (http://www.brainspan.org/). Datasets from four brain regions, including the
ventral frontal cortex (VFC), medial frontal cortex (MFC), dorsal frontal cortex (DFC) and
primary somatosensory cortex (S1C) were used for developmental expression analysis. Genes
from GO:0050769 and GO: 0007268, representing neurogenesis and synaptic genes respectively
were first extracted from the Brainspan dataset and the average RPKM value in VFC was
calculated and plotted across developmental time. Differentially expressed genes (DEGs) upon
PHF6 KO were divided into up-regulated and down-regulated genes. These genes were extracted
from BrainSpan data for each brain region, and the average RPKM was calculated and analyzed
across the developmental time. A custom R script was used for analyses.
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Biocytin injection and post-hoc staining
Biocytin labeling was performed as described (Huang et al., 2010). Intracellular
recording solution containing 1% biocytin was loaded into layer II stellate neurons in the
entorhinal cortex from P7-9 (C99F: n=8; control: n=7), P14-16 (C99F: n=6; control: n=7) and
P21-25 (C99F: n=7; control: n=7) animals through recording electrode. Slices were fixed in 4%
PFA for 2 hours. Slices were subjected to histochemical analyses with Alexa-Fluor 488conjugated Avidin (1:1000) for 40C overnight.

Statistical analyses
Statistical analyses were performed using GraphPad Prism 6.0, and SPSS (v2.5)/Systat
statistical software packages. Independent t-tests, one-sample t-tests, factorial ANOVAs,
including repeated measures (rm) ANOVAs were used where appropriate. The Huynh-Feldt
correction was applied to all within-subjects effects containing more than two levels to protect
against violations of sphericity/compound symmetry assumptions underlying rmANOVA
models. Specific planned comparisons were conducted to provide further clarification of
significant interactions between main factors. Simple main effects were calculated for
significant main effects of factors, and Bonferroni corrections were used for multiple
comparisons. Probability value for statistical significance for all analyses was P < 0.05.
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Chapter 4:
Conclusions and Future Directions
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Significance
In this study, we report our discoveries on pathogenic mechanisms underlying BörjesonForssman-Lehmann syndrome (BFLS), a well-known cause of X-linked intellectual disability.
Although mutations of the transcriptional regulator PHF6 are known to cause BFLS, the
pathogenic mechanisms underlying BFLS have remained to be elucidated. Using CRISPR-Cas9
technology, we have generated the first mouse model of BFLS, harboring the patient mutation
that replaces Cysteine 99 within the PHD domain of PHF6 with phenylalanine (C99F). PHF6
C99F knock-in mice display deficits in cognitive functions as well as reduced threshold to
seizures. In electrophysiological studies, the intrinsic excitability of entorhinal cortical stellate
neurons is increased, providing a mechanistic basis for seizure predisposition upon PHF6
deficiency. Transcriptomic analysis of the cerebral cortex in PHF6 C99F knock-in and PHF6
knockout mice show that PHF6 promotes the expression of neurogenesis genes and
concomitantly suppresses the expression of synaptic genes. Remarkably, PHF6-regulated genes
are overrepresented in gene signatures and modules that are deregulated in the brain of patients
with autism spectrum disorders. Our findings advance our understanding of the mechanisms
underlying BFLS pathogenesis and offer new links between BFLS and autism spectrum
disorders.
Intellectual disability (ID) is a prevalent developmental disorder that affects 1% to 3% of
the general population. With no effective treatments, these disorders pose enormous economic
costs to society. There is thus an urgent need to better understand the pathogenesis of ID. BFLS
was identified over five decades ago as a syndrome of X-linked ID that also features epilepsy.
Although rare, BFLS now represents a widely known cause of ID. The generation of the first
mouse model provides unprecedented opportunities for understanding the pathogenesis of ID as
demonstrated in our study in behavior, electrophysiological, transcriptomics, and bioinformatics
analyses. In addition, these mice provide the opportunity for the field to identify novel therapies
for neurodevelopmental disorders of cognition.
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One of the most exciting aspects of our study is that bioinformatics analyses of the alterations of
gene expression in the cerebral cortex has revealed that PHF6-regulated genes are
overrepresented in gene signatures and modules that are deregulated in the brain of patients with
autism spectrum disorders. Strikingly, we have recently identified a patient with autism spectrum
disorder that harbors a nonsense mutation of Cysteine 305 within the second PHD domain of
PHF6. Our findings suggest that autism may represent an underappreciated component of BFLS.
In summary, our study advances understanding of the cellular and molecular underpinnings of
BFLS, and lays the foundation for potential treatments for neurodevelopmental disorders of
cognition. Here I highlighted a few exciting new questions this study has opened up.

Future Directions
The biological consequences of PHF6 in regulating neural maturation
Transcriptomic analyses of PHF6 knockout and control mice have revealed potential
molecular mechanisms through which PHF6 regulates cell state. In particular, we found that
PHF6 activates neurogenic genes and represses synaptic genes, by which maintaining neurons at
an immature state. Upon PHF6 loss, the developmentally upregulated genes including synaptic
genes were unregulated at an earlier time point. Concomitantly, the developmentally
downregulated genes including neurogenic and cell differentiation-related genes were
downregulated in advance.
To determine the biological consequences of the precocious differentiation in PHF6
knockout mice, two biological events including neural differentiation and synaptogenesis could
be tested. Interestingly, the dendritic spine development did not seem to be advanced in the
entorhincal cortex layer II stellate neurons in the C99F mice, even with the moderate correlation
between C99F and PHF6 knockout transcriptome. Because the bioinformatics analyses were
primarily based on differentially regulated genes upon PHF6 knockout, it is important to
determine the biological consequence of precocious differentiation in the PHF6 knockout mice.
With the impossibility of testing synaptogenesis in the developing PHF6 knockout mice in vivo,
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due to perinatal lethality, it is also important to determine whether the neurons in vitro undergo
advanced synaptogenesis.
When neurons first exist mitotic cycle, they immediately start expressing doublecortin
(DCX). DCX is subsequently downregulated once the neurons become mature (Donato et al.,
2017). Therefore, to test whether the differentiation process is advanced in the PHF6 knockout
neurons, DCX could be used as an immature neuron marker. For future study it will be
interesting to test the necessity and sufficiency of PHF6 in preventing neuronal premature
differentiation by label the neurons with the same birthdate and follow through their
development and analyzed the expression of DCX in the synchronized neural population to
assess neural maturation in the context of PHF6 knockout or overexpression.

What is the molecular mechanisms underlying BFLS pathogenesis?
The gene expression changes upon PHF6 knockout provide clues for studying the
function of PHF6, whereas the gene expression alterations in PHF6 C99F give insights on the
molecular mechanisms underlying BFLS. Through bioinformatics analyses, we discovered that
the transcriptomic changes in PHF6 knockout and C99F were moderately correlated. In other
analyses, we identified that the genes specifically altered in the PHF6 knockout were involved in
mechanism in maintaining immature cell state, whereas the genes that were highly correlated in
the two genotypes occupy only a small fraction and were involved in other mechanisms such as
cell signaling and cilia. Up until now, what goes awry molecularly in PHF6 C99F and the
molecular mechanisms underlying BFLS pathogenesis remains unclear.
In the bulk RNAseq experiments, we did not identify many differentially expressed genes
in the PHF6 C99F mice. Notably, when we used DEseq2, a more stringent way for differential
gene expression analysis, only one gene, PHIP, was detected (data not shown). Since PHF6
C99F significantly altered the neural excitability and later on fear learning, some developmental
changes due to PHF6 C99F knock-in must have happened. The small number of differentially
expressed genes detected through bulk RNAseq could be due to the dilution effect from tissue
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heterogeneity. Interestingly, the neural excitability was increased in entorhinal cortex layer II
stellate neurons, while remained same in layer II/III pyramidal neurons of the somatosensory
cortex in PHF6 C99F mice compared to WT, suggesting that PHF6 regulate biological function
in a cell type and brain region specific manner. It is therefore critical to determine whether the
gene expression of PHF6 is also regulated in a cell-type specific manner.
The discovery of the altered intrinsic excitability in the entorhincal cortex layer II stellate
neurons specifically has provided important clue on which cell types to perform transcriptomic
analyses. In future studies, it would be essential to understand the gene expression changes and
potential epigenetic alterations in an enriched cell type, such as entorhincal cortex stellate
neurons in the PHF6 C99F mice. These systematic profiling of C99F mice could shed light on
the molecular pathogenesis of BFLS in a cell-type specific manner.

Epigenetic regulation of transcription by PHF6
PHF6 contains two PHD-like zinc finger domains, which gives potential for PHF6 to
bind to DNA or modified histones. Studies have shown that PHF6 interacts with transcriptional
elongation complex, PAF1 and nucleosome remodeling complex, NuRD. Recent studies have
provided insights on how PHF6 regulate gene expression along with chromatin accessibility in
B-cell leukemia. Particularly, loss of PHF6 led to downregulation of B-cell developmental genes,
and activation of T-cell signaling genes, by which gave rise to lymphoma with mixed lineages
(Feliciano et al., 2017). The expression alteration of B-cell and T-cell lineage was correlated
with chromatin accessibility. Similarly, in our study, upon PHF6 loss, differentiation genes were
downregulated and synaptic genes were upregulated, leading to precocious differentiation,
suggesting PHF6 can act both as a transcriptional activator as well as repressor. However, how
PHF6 regulates gene expression, perhaps through epigenetic mechanisms and the direct targets
of PHF6 in mouse cortex remains unknown. For future studies, it is critical to understand the
biochemical function of PHF6 in the developing cortex. Important specific questions include:
1. Where does PHF6 bind in the genome in the developing cortex?
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In the preliminary studies, we performed PHF6 ChIP-seq experiments to investigate its
genome occupancy. Using two biological replicates, we identified over 2000 PHF6 binding sites;
the majority of them were at promoters. PHF6 binding is positively correlated with gene
expression and active histone markers (See Appendix Figure S9), suggesting that PHF6 mainly
binds to active promoters. One caveat of the experiment was that instead of using the PHF6 KO
or IgG as negative control, we used PHF6 C99F as a negative control because of dramatic
reduction in PHF6 protein level in vivo. Even though, we were able to identify PHF6 signals
across the genomes, those peaks were identified with less confidence due to improper negative
control. In future studies, it is critical to use PHF6 WT and KO cortex to perform PHF6 ChIPseq experiments to understand the genome occupancy of PHF6. Our prediction though, is still the
same that PHF6 binds to active gene promoters.
2. Through what epigenetic mechanisms does PHF6 regulate transcription?
Previously, PHF6 has been shown to interact with NuRD complex, which contains
histone deacetylase proteins. We also observed endogenous interaction of PHF6 with NuRD
complex subunits (See appendix Figure S6). Therefore, we hypothesize that PHF6 can regulate
gene expression through epigenetic mechanisms. To test that hypothesis, PHF6 control and KO
cortex could be used to profile for DNA hypersensitivity, chromatin opening and histone
modifications. In fact, in our preliminary work profiling histone modifications ChIP-seq using
H3K27ac, H3K4me3 and H3K9/14ac antibodies in three pairs of PHF6 control and C99F cortex,
we found there was little or no changes in histone peaks or histone density at PHF6-regulated
genes (identified upon PHF6 knockout) (Figure S9). This observation was somewhat expected
because histone modification is correlated with gene expression and there was not many genes
altered in the C99F cortex from bulk RNAseq. It is possible that PHF6 functions downstream of
histone modification in regulating gene expression. However, we could not rule out the potential
effect of PHF6 on histone modification under PHF6 knockout condition. We reason that
understanding chromatin opening, histone modification and DNA hypersensitity sites in PHF6
knockout cortex can help understand where PHF6 functions in the regulation of transcription.
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Is entorhinal cortex-hippocampal pathway disrupted in mouse model of BFLS?
The discovery of entorhincal cortex (EC) layer II stellate neuron (L2) hyperexcitability in
the PHF6 C99F mice shed light on the potential circuit that might be disrupted in the mouse
model of BFLS. The circuit connecting EC and hippocampus (HPC) has been studied for
decades. Medial entorhinal cortex layer II stellate neurons (MEC-L2) projects to dentate gyrus
(DG) of hippocampus, which then projects to CA3, followed by CA1, lateral entorhinal cortex
layer V pyramidal neurons (LEC-L5) and LEC layer II pyramidal neurons (LEC-L2). This circuit
is implicated in multiple behavior paradigm as well as seizures (Janz et al., 2017, Kitamura et al.,
2015). Since many of the behavioral impairments observed in our PHF6 C99F are pointing to
this circuit malfunction, it will be important to understand whether stellate neurons alone or the
EC-HPC circuit is implicated in the BFLS. First of all, detailed electrophysiological and circuitmapping analyses could be performed to understand major effect of stellate neuron
hyperexcitability on downstream target cells such as DG granule neurons. Another aspect to
analyze the circuit is measuring circuit maturation (Donato et al., 2017). Previous studies have
suggested that the excitability of MEC-L2 stellate neurons drive the maturation of EC-HPC
circuit (Donato et al., 2017). Silencing of the MEC-L2 stellate neurons disrupts the maturation of
EC-HPC circuit. In our mouse model of BFLS, entorhinal cortex layer II stellate neurons display
increased

intrinsic

excitability.

Therefore,

EC-HPC

circuit

maturation

could

be

disrupted/advanced in the PHF6 C99F mice as a result of stellate neuron hyperexcitability.

How do entorhinal cortex layer II stellate neurons function during contextual fear
learning?
In our study, we found that PHF6 C99F mice displayed impaired contextual fear
memory. This impairment was reproducibly observed in two independent cohorts of mice.
During contextual fear conditioning, the animals need to first encode a representation of the
context (context encoding), associate the context representation with unconditioned stimulus
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(US) (in this case, foot shock); then both context memory and context-US association undergo
memory consolidation (Maren et al., 2013). The step of memory encoding is necessary for
memory consolidation. In our study, it is difficult to understand whether the impaired contextual
fear was because of lack of memory encoding or consolidation. Therefore, in the future studies, it
is important to understand which part of contextual fear memory is disrupted, context encoding
or memory consolidation? Using more detailed behavior paradigm such as context
discrimination assay can help dissect out the fear memory impairment.
Also, studies have suggested that memory encoding and consolidation could happen in
different brain regions. The context information is presented in the entorhincal cortex stellate
neurons before reaching the granule cells in the DG, whereas the memory consolidation mainly
occurs in the hippocampus. Interestingly, MEC layer II stellate neurons, projecting to DG
granule cells, are involved in context-specific encoding, activation of CA3 pyramidal cells and
contextual fear memory. In particularly, MEC layer II stellate neurons show context-specific
calcium activity, and are critical for Discriminatory Encoding in CA3 regions, which then
facilitates contextual fear memory. With the intrinsic hyperexcitability observed in the PHF6
C99F EC layer II stellate neurons, it will be interesting to analyze whether these cells have
abnormal neural coding through analysis of their Ca2+ responses, which in turn affects neural
coding.

Altered neuronal and circuits excitability in BFLS
The discovery of hyperexcitability in the EC layer II stellate neurons associated with
increased input resistance and reduced cell capacitance has opened a new area of investigation on
what ion channel(s) might be involved. Importantly, in the preliminary experiment, we did not
find increased EPSPs in the stellate neurons, suggesting the increased excitability is not due to
the elevation of the excitatory input from upstream neurons (data not shown). Instead, the
increased excitability is likely due to cell intrinsic alteration of the channel activities. In the field
of neural excitability, multiple factors could be contributing to alteration of the action potential.
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For example, the noninactivating persistent sodium current is increased in the EC layer III
pyramidal neurons of FMRP KO mice, leading to the reduced action potential threshold and
neural hyperexcitability (Deng and Klyachko, 2016). Additionally, reduction in Kv4.2 (Gross et
al., 2011), and altered HCN channel expression (Brager et al., 2012) have also been linked to
abnormal excitability in the FMRP KO mouse model. In our case, the decreased the action
potential threshold could be resulting from increased sodium current, or decreased potassium
current. A defect in the action potential rising phase indicates sodium channelopathy, whereas
the repolarization phase disruption could be due to defected potassium channel, and abnormal
action potential duration could be due to voltage-gated potassium channels. Therefore, a detailed
investigation of action potential waveform is critical for identification of the channelopathy in
PHF6 C99F stellate neurons.
Due to heterogeneity of the cell types in the cortex, neurons response differently upon
constitutive genetic mutation. This is most evident in the field of electrophysiological research in
FMRP knockout mice (Contractor et al., 2015; Deng and Klyachko, 2016; Deng et al., 2013; Lee
and Jan, 2012). For example, studying of somatosensory cortex layer V principle cells in the
FMRP model have suggested that pyramidal tract (PT) neurons show altered HCN channel,
while HCN current remains intact in intratelecephalic tract (IT) neurons upon FMRP knockout.
EC layer III pyramidal neurons exhibit reduced action potential threshold caused by increased
persistent sodium current, whereas EC layer II stellate neurons display normal excitability in the
FMRP KO mice (Deng and Klyachko, 2016). Therefore, neural excitability in these XLID
models is affected in a brain region and cell type specific manner. For future investigation, it will
be interesting to understand the affect of PHF6 loss on neural excitability in different brain
regions and cell types, possibly combining the molecular tools such as translating-ribosomeaffinity-purification-seq (TRAP-seq) or INTACT for in-depth molecular mechanisms.

The link between BFLS and ASD
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The mouse model of BFLS has behavioral impairments in the social interaction; in
particular, the PHF6 C99F mice displayed normal social motivation, but reduced social
recognition. Interestingly, PHF6 C99F mice also displayed reduced ambulatory activity and
vertical rearing frequency in the open field tests. These data suggest that PHF6 C99F mice could
also be lack of interest/curiosity, which is displayed in other autism spectrum disorder (ASD)
mouse models. However, we did not identify behavioral defects in the ultrasonic vocalization or
marble burying (data not shown), which measure communication and stereotypic movements in
the mouse. In our PHF6 C99F mouse model, we did not identify major autistic-like phenotypes.
However, the identification of ASD patient harboring C305X mutation and the gene enrichment
analyses on PHF6-regulated genes with ASD relevant genes have raised the question whether
ASD is presented in BFLS in an underappreciated rate. Here, we raised the possibility of linking
BFLS and ASD both at a clinical setting and in basic research setting. In the future studies, it
would be interesting to test whether the newly generated BFLS mouse models (with different
patient mutations) harbor autistic-like behaviors.
Another important aspect of the BFLS is the disease diagnosis in the female patients.
Interestingly, BFLS has been diagnosed in the female patients only in recent years after
combining exome sequencing. This is because female patients of BFLS display a more diverse
picture of syndromic and behavioral features compared to male patients. Also, it seems that
female patients of BFLS harbor mutations that might be more deleterious, ranging from whole
region deletion to duplication of exon 4 and 5 (Jahani-Asl et al., 2016). The C305X mutation
case linking BFLS and ASD is also found in a female patient. Therefore, in the impossibility of
testing the autistic-like phenotype in our PHF6 KO mice, it will be worthwhile to characterize
the heterozygous PHF6 KO female mice, since the heterozygous PHF6 KO female could
represent another BFLS disease model to study the disease from a sexual dimorphism
perspective.
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PHF6-NuRD complex interaction

INTRODUCTION
The nucleosome remodeling and deacetylase (NuRD) complex is a major chromatin
remodeling complex found in mammalian cells. The NuRD complex comprises at least seven
proteins: the histone deacetylases Hdac1 and Hdac2, two histone-binding proteins RbAp46/48,
CHD3/4 proteins that have ATP-dependent nucleosome-remodeling activity, mta1/2, MBD3, as
well as P66. NuRD complex has been widely studied in cancer and embryonic stem cells (ESC)
(Lai and Wade, 2011). NuRD complex aberrantly regulate gene repression through deposition of
epigenetic repressive marks in acute promyelocytic leukemia (APL) (Morey et al., 2008). Also,
balanced targeting of NuRD by lineage-specific transcription factors facilitates lymphocyte
development and prevents leukemogenesis (Zhang et al., 2012). In ES cells, NuRD complex
subunits MBD3 has been shown to facilitate ESC differentiation and inhibits ESC self-renewal
in a Lif-independent manner (Kaji et al., 2006). Recently, two de novo mutations in NuRD
subunit-p66alpha were found in patients with severe intellectual disability (Willemsen et al.,
2013). As it turns out, NuRD complex also plays a role in neural development and controls
circadian rhythm by regulating gene expression (Kim et al., 2014; Sparmann et al., 2013;
Yamada et al., 2014). NuRD complex is known to specifically repress genes essential for
synaptogenesis in cerebellar granule neurons (Yamada et al., 2014). During cortical
development, NuRD can recruit Polycomb repressor complex 2 (PRC2) to regulate the
neurogenic to astrogenic switch (Sparmann et al., 2013).
In the previous studies, PHF6 has been shown to interact with NuRD complex subunits in
the 293T cells (Todd et al., 2015). This interaction was further predicted by the crystal structure
analyses of second PHD domain of PHF6 (Liu et al., 2014). However, in B-cells, PHF6-NuRD
interaction was not observed (Feliciano et al., 2017), suggesting that PHF6-NuRD interaction
could be cell type specific. Additionally, in our RNA-seq analyses upon PHF6 knockout, about
50% genes were upregulated and another 50% were downregulated, indicating that PHF6 might
97

regulate gene expression both through transcriptional activation and repression. Previous study
by Zhang et al. demonstrated endogenous interaction of PHF6 with PAF1 elongation complex,
giving a potential activation mechanism of PHF6 in regulating transcription. However, whether
PHF6 interact with NuRD complex in neurons, potentially by which to repress gene expression
remains unknown.

RESULTS
To test whether PHF6 and NuRD complex interact, we first performed coimmunoprecipitation (co-IP) experiments analyzing PHF6 interaction with NuRD complex
subunits in the 293T cells and in cortex. As expected, overexpression of FLAG-tagged PHF6
plasmid was able to pull down endogenous NuRD complex subunits (data not shown). Similarly,
in the reciprocal co-IP by immunoprecipitating FLAG-tagged MTA1 and CHD4, PHF6 was also
co-immunoprecipitated (data not shown). Additionally, to investigate the interaction of PHF6
and NuRD complex under more physiological condition, we performed immunoprecipitation of
endogenous PHF6 in E18 cortex, and immunoblotted with NuRD complex subunits.
Interestingly, we observed similar PHF6-NuRD interaction endogenously (Figure S6a). In the
reciprocal co-IP experiments by either RBAP48 or CHD4, PHF6 was also coimmunoprecipitated (Figure S6b). These data suggested that PHF6 could interact with NuRD
complex subunits in the developing cortex. We next asked whether the PHF6 was part of the
NuRD complex in the developing cortex. Additional co-IP experiments were performed by
immunoprecipitating RBAP48, followed by stringent washing conditions. The NuRD complex
interaction was present after high salt wash, whereas the PHF6-NuRD complex interaction was
abolished (Figure S6c), suggesting that PHF6 was not part of the NuRD complex in the
developing cortex.
To characterize which domain of PHF6 was important for the interaction with the NuRD
complex subunits, we overexpressed the FLAG-tagged PHF6 with different domain deletions of
PHF6 proteins in 293T cells, and performed co-IP experiments looking at endogenous NuRD
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complex subunits interaction. Notably, all the truncated PHF6 protein that we tested showed
interaction with NuRD (Figure S6d-e). Interestingly, by deleting the regions containing the first
or second PHD domain resulted in an increase in the interaction with NuRD complex subunits
including MTA1/2, HDAC1 and CHD4, suggesting that the two PHD domains might be
competing with each other in NuRD interaction.
The discovery of interaction of PHF6-NuRD complex in cortex has shed light upon the
potential mechanism through which PHF6 regulates transcription through gene repression. In
future studies, it would be important to first determine the effect of the subunits of NuRD
complex also in neural development, such as cortical neuronal migration, and to understand how
transcription can be regulated through the PHF6-NuRD interaction.

METHODS
Co-immunoprecipitation
Tissues or cells were lysed in a lysis buffer containing 150 mM NaCl, 20 mM Tris-HCl
(pH 7.5), 1% Triton-X, and protease inhibitor cocktail (Sigma-Aldrich). For
immunoprecipitation of Flag-tagged proteins, lysates were incubated with anti-Flag M2 agarose
beads (Sigma-Aldrich) for 3 hr at 4°C and washed five times with lysis buffer. For
immunoprecipitation of endogenous proteins, lysates were incubated with the appropriate
primary antibody overnight at 4°C. The antibody-protein complexes were purified with protein G
Sepharose 4 Fast Flow beads (GE Healthcare) for 2 hr at 4°C and washed five times with lysis
buffer. The immunoprecipitated protein complexes were then analyzed by SDS-PAGE and
transferred to a nitrocellulose membrane for immunoblotting analyses with the appropriate
primary antibodies and horseradish peroxidase-conjugated secondary antibodies (Jackson
ImmunoResearch).
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Figure S6. The interaction of PHF6 and NuRD complex.
(a) PHF6 was immunoprecipited from lysate of E18 cortex and unveiled in Western blot using
antibodies against CHD4, MTA1/2, HDAC1, RBAP48 and PHF6. IgG was used as a negative
control. PHF6 interacts with NuRD complex subunits.
(b) CHD4 or RBAP48 was immunoprecipitated from lysate of E18 cortex and unveiled in
Western blot using antibodies against CHD4, MTA1/2, HDAC1, PHF6 and MBD3. IgG was
used as negative control. In the reciprocal IP, PHF6 interacts with NuRD complex.

100

(c) RBAP48 was immunoprecipitated from lysate of E18 cortex, followed by combined high salt
(HS) and low salt (LS) wash, and unveiled in Western blot using antibodies against CHD4,
HDAC1 and PHF6. IgG was used as negative control. PHF6 interaction with NuRD complex is
abolished upon high salt wash.
(d) FLAG-tagged PHF6 with different truncations expressed in 293T cells was
immunoprecipitated with anti-FLAG antibody. Samples were unveiled in Western blot using
antibodies against CHD4, MTA1/2, HDAC1 and FLAG. Truncated PHF6 remains interactions
with NuRD complex.
(e) Schematic of PHF6 protein structure with different truncations. Yellow box:
nuclear/nucleolar localization sequences. Dot line: PHF6 truncated region.
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PHF6 knockout mouse displays excitatory/inhibitory imbalance
In the process of backcrossing the PHF6 knockout mice with C57BL6 mice, we noticed
that the mice started to die around birth. We therefore also kept the PHF6 knockout line in the
hybrid background of C57BL6 and CBA mice. To our surprise, PHF6 knockout mice kept in
C57BL6/CBA background were born with expected Mendelian ratio, able to survive into
adulthood and were smaller than the control mice. More interestingly, PHF6 knockout mice
develop spontaneous seizure around 8 month old. Following this observation, we asked whether
the neural circuit in the PHF6 knockout mice was hyperactive. To test the hypothesis, we
performed whole-cell patch clamp and measured the evoked inhibitory postsynaptic current
(IPSC) and excitatory postsynaptic current (EPSC) in CA1 pyramidal neurons in the
hippocampus of PHF6 knockout and control mice. Interestingly, with the same amplitude of
EPSCs evoked, the control CA1 neurons were able to recruit IPSCs with larger amplitude
compared to PHF6 knockout neurons (Figure S7a,b). When we quantified the inhibitoryexcitatory balance by calculating the ratio of IPSC to EPSC amplitude (I/E), we found the PHF6
knockout neurons displayed reduced I/E ratio (Figure S7c-e). These data suggest that the ability
of inhibitory input recruitment was reduced in the PHF6 knockout CA1 neurons. Additionally,
no differences were observed in the spontaneous EPSC frequencies, whereas spontaneous IPSC
(sIPSC) frequencies were largely reduced in the PHF6 knockout CA1 neurons, while the
amplitudes were unchanged (Figure S7f-g).
These data have raised important questions for future investigation, what aspects of the
presynaptic defects led to the reduction in sIPSC frequency in the PHF6 knockout neurons? Does
PHF6 have specific roles in interneurons and excitatory neurons?
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Figure S7. Excitatory/inhibitory imbalance in PHF6 knockout mice.
(a-b) Whole cell patch clamp of CA1 pyramidal neurons. Sample trace of evoked EPSC and
IPSC in WT (a) and PHF6 KO (b) cells.
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(c) The ratio of IPSC to EPSC amplitude (I/E) was calculated for each cell. PHF6 KO cells
display reduced I/E ratio.
(e) Quantification of I/E ratio in WT and PHF6 KO cells.
(f-g) spontaneous EPSCs (f) by holding at -70mV and IPSCs (g) by holding at -20mV in the
CA1 pyramidal neurons in WT and PHF6 KO mice. PHF6 KO cells have similar EPSC
amplitude and frequencies, but reduced IPSC frequencies.
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Cellular characterization of mouse model of PHF6 deficiency
Because PHF6 is highly expressed during early cortical development (Figure 1), prior to
the detailed behavioral characterization, we first performed a series of cellular phenotyping
covering early biological events of cortical development in the PHF6 C99F knock-in mice. We
first performed BrdU labeling at E17 brain. Little or no differences were detected comparing
control and PHF6 C99F cortices (Figure S8a). We next used the superficial layer marker, Cux1
and deep layer marker, Ctip2 to characterize whether cortical layering was affected. Notably, no
obvious differences were detected (Figure S8b). In other analysis, we used electrophysiology to
characterize the intrinsic electrical properties of layer II/III pyramidal neurons in the
somatosensory cortex. There were little or no differences in resting membrane potential, intrinsic
excitability, membrane capacitance in PHF6 C99F cells (data not shown). Biocytin injection in
the layer II/III pyramidal neurons at P17-21 also showed similar cell morphology (Figure S8c)
and spine density (data not shown) with the control cells. Altogether these data suggest that
PHF6 C99F knock-in mice did not exhibit gross morphological defects in the brain.
Notably, in the characterization of PHF6 knockout brains, we noticed a consistent
enlargement of lateral ventricle in the PHF6 knockout mice at P0 (Figure S8d). This enlargement
of lateral ventricle was not observed at E18 (data not shown), suggesting that the increased in
lateral ventricle did not occur until the mice were born. Enlarged ventricle has also been shown
in the patient of BFLS (Berland et al., 2011; Zweier et al., 2013). Anecdotally, we have observed
many “cilia” related genes decreased upon PHF6 knockout. In fact, the correlated genes between
KO and KI cortex (KO-KI common) are enriched for GO terms including “cilia”. These
evidence pointing towards to the ependymal cells defects. However, the mechanisms and cell
type underlying the enlarged ventricle remains to be discovered.
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Figure S8. Cellular characterization of PHF6 KO and C99F knock-in mice.
(a) E17 pregnant female were pulsed with BrdU for 2 hours. Brains from E17 embryos were
collected, sectioned and subjected to immunohistochemistry analyses using antibodies against
BrdU. Hoechst was used as counter staining. Little or no differences in BrdU+ cells between
PHF6 C99F knock-in and WT mice.
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(b) Brain sections of P2 mice were subjected to immunohistochemistry analyses using antibodies
against Cux1 and Ctip2. Cortical layering seems similar in WT and PHF6 C99F knock-in mice.
(c) P17-21 pyramidal cells from somatosensory cortex were injected with biocytin, followed by
post-hoc staining with Avidin-488. Dendrite arborizations were subjected to Sholl analysis. WT
and PHF6 C99F cells have similar dendrite arborization.
(d) Brain sections from P0 mice were subjected to immunohistochemistry analyses using
Hoechst. Ventricle size was measured in PHF6 KO and WT mice. PHF6 KO mice display
enlarged ventricle compared to WT mice.
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PHF6 binds to active gene promoters
In our study, we described how PHF6 regulates gene expression at the genome-wide
level. However, detailed mechanisms on PHF6 regulation of transcription remain unexplored.
Here, in our preliminary work, we characterized the PHF6 genome occupancy in the P0 mouse
cortex by performing ChIP-seq experiments of PHF6. Interestingly, in PHF6 ChIP-seq
experiments, we identified approximately 2000 peaks of PHF6 from two biological replicates.
The PHF6 peaks were found in mainly at the promoter regions (Figure S9a). Therefore, we
focused on the PHF6 occupancy at the active promoters by intersecting all the promoters with
H3K4me3 peaks in the P0 cortex. We found that PHF6 density was enriched at the active
promoters, and this enrichment was depleted in the PHF6 C99F mice. When we grouped the
expressed genes in the P0 cortex by gene expression, we found that PHF6 density was positively
associated with increase in gene expression (Figure S9c). In other analyses, most of PHF6 peaks
were also enriched for H3K27ac and H3K4me3 markers labeling active transcribed gene
promoters in the genome (Figure S9d). These data suggest that PHF6 binds to active promoter,
and its occupancy is positively correlated with gene expression. Notably, PHF6 peaks were
enriched for GO terms including zinc finger, transcription factors and abnormal nervous system,
suggesting that these peaks were specific for the nervous system.
To understand the relationship between PHF6 binding and gene expression, we compared
the PHF6 ChIP signals with misregulated genes upon PHF6 knockout. Interestingly, for both
downregulated and upregulated genes upon PHF6 loss, similar density of PHF6 signal was
observed at those gene promoters (Figure S9f), suggesting that PHF6 could bind to gene
promoters to regulate gene expression. Our preliminary studies have suggested that PHF6 can
interact with NuRD complex in the developing cortex (Figure S6a). NuRD complex contains
histone deacetylase proteins HDAC1/2 to regulate H3K27ac and H3K9/14ac, through which
repress transcription (Yamada et al., 2014). Therefore, we asked whether PHF6 could regulate
histone modifications, perhaps through which regulates gene expression. We therefore performed
H3K27ac, H3K4me3 and H3K9/14ac ChIP-seq in both WT and C99F cortex. Interestingly, the
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density of H3K27ac did not changed in for all the expressed genes in the genome, or for the
downregulated and upregulated genes upon PHF6 knockout, suggesting that PHF6 could regulate
gene expression through histone-independent mechanisms.
One caveat of the experiment was that instead of using the PHF6 KO or IgG as negative
control, we used PHF6 C99F as a negative control because of dramatic reduction in PHF6
protein level in vivo. Even though, we were able to identify PHF6 signals across the genomes,
those peaks were identified with less confidence due to improper negative control. In future
studies, it is critical to use PHF6 WT and KO cortex to perform PHF6 ChIP-seq experiments to
understand the genome occupancy of PHF6. Our prediction is still that PHF6 is localized at
active gene promoters.
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Figure S9. PHF6 binds to active promoters.
(A) The distribution of PHF6 peaks across the genome.
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(B) PHF6 density at H3K4me3-bound promoters in WT and C99F cortex.
(C) PHF6 density at gene promoters of genes with low (Q3), medium (Q2) and high (Q1)
expression.
(D) (Left) heatmap of PHF6 peaks in PHF6 WT and C99F cortex. (Right) H3K27ac and
H3K4me3 density in all PHF6 peaks.
(E) GO terms for PHF6 peaks analyzed by GREAT.
(F) PHF6 density in upregulated and downregulated genes upon PHF6 knockout.
(G) H3K27ac density of WT and C99F cortex in all genes (left), downregulated (middle) and
upregulated (right) genes upon PHF6 knockout.
(H) Examples of epigenome browser shot of PHF6 and H3K27ac peaks.
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